



**Het programma werd samengesteld met inbreng van de volgende verenigingen en secties:**

Nederlandse Vereniging voor Gastroenterologie  
Nederlandse Vereniging voor Gastrointestinale Chirurgie  
Nederlandse Vereniging voor Hepatologie  
Nederlandse Vereniging van Maag-Darm-Leverartsen

*Secties:*

Netherlands Society of Parenteral and Enteral Nutrition  
Sectie Experimentele Gastroenterologie (DEG)  
Sectie Gastrointestinale Endoscopie  
Sectie Neurogastroenterologie en Motiliteit  
Sectie Gastrointestinale Oncologie  
Sectie Inflammatoire Darmziekten IBD  
Sectie Kinder-MDL  
Verpleegkundigen & Verzorgenden Nederland - MDL

Belangrijke mededeling over de aanwezigheid van farmaceutische industrieën	3
--	---

**Woensdag 20 maart 2019**

Post Ecco, ochtend – Brabantzaal	4
Symposium: Jong gekregen, oud gehouden, middag – Brabantzaal	4
Symposium NVGE: Op het grensvlak van pathologie en endoscopie, middag – Brabantzaal	5
State of the art lecture: Prof. dr. Julia Wendon, Acute Chronic Liver Failure	6
President select	6
Uitreiking NVGE Gastrointestinale Research Award 2019 en voordracht door de prijswinnaar	6
Ledenvergadering, ochtend, Auditorium	7
Symposium NVH: Do's en don'ts van chirurgie bij levercirrose, ochtend, Auditorium	7
Symposium Sectie Gastrointestinale Endoscopie: Future in Endoscopy, middag – Auditorium	7
Symposium NVMDL: Opioiden gebruik en misbruik, middag - Auditorium	8
Meet the expert sessie: Pancreascarcinoom, ochtend – Baroniezaal	8
Ledenvergadering en prijsuitreikingen NVGE, Baroniezaal	8
Abstractsessie Sectie Inflammatoire Darmziekten, middag - Baroniezaal	9
Abstractsessie Sectie Inflammatoire Darmziekten, middag – Baroniezaal	11
Meet the expert sessie: IgG gemedieerde ziekte, ochtend – Parkzaal	12
Abstractsessie Sectie Gastrointestinale Oncologie, middag – Parkzaal	13
Abstractsessie Sectie Gastrointestinale Endoscopie, middag – Parkzaal	16
Meet the expert sessie: Pancreascarcinoom, middag – Zaal 80	18
Meet the expert sessie: IgG gemedieerde ziekte, middag – Zaal 81	18
Digitalisering in de zorg, middag – Zaal 81	18

**Donderdag 21 maart 2019**

Symposium NVGIC 1, onderwerp: IBD, ochtend – Beneluxhal	19
Symposium NVGIC 2, onderwerp: Fluorescentie en het colorectaal carcinoom, ochtend – Beneluxhal	19
Symposium NVGIC 3, onderwerp: Highlights from lowlands, middag – Beneluxhal	20
Abstractsessie Sectie Gastrointestinale Oncologie, ochtend – Auditorium	20
Symposium Sectie Gastrointestinale Oncologie: Shared decision making – Auditorium	22
Astractsessie Sectie Experimentele Gastroenterologie, ochtend – Baroniezaal	22
Abstractsessie Nederlandse Vereniging voor Gastroenterologie, ochtend – Parkzaal	25
Abstractsessie Neurogastroenterologie & Motiliteit, ochtend – Parkzaal – Auditorium	26
Abstractsessie Nederlandse Vereniging voor Gastrointestinale Chirurgie, ochtend – Zaal 80	27
Programma cursorisch onderwijs in MDL-ziekten, middag – Brabantzaal	30
Programma V&VN: ochtend programma – Brabantzaal	32
Programma V&VN: middag programma – Auditorium, Baroniezaal, Parkzaal	33

**Tijdstippen diverse ledenvergaderingen woensdag:**

Nederlandse Vereniging voor Hepatologie	20 maart	09.30 uur – Auditorium
Sectie Inflammatoire Darmziekten	20 maart	11.15 uur – Brabantzaal
Nederlandse Vereniging voor Gastroenterologie	20 maart	11.30 uur – Baroniezaal
NVMDL i.o.	20 maart	12.00 uur – n.t.b.

**Tijdstippen diverse ledenvergaderingen donderdag:**

Nederlandse Vereniging van Maag-Darm-Leverartsen	21 maart	08.00 uur – Zaal 82-83
V&VN MDL	21 maart	09.30 uur - Brabantzaal

## **Belangrijke mededeling over de aanwezigheid van farmaceutische industrieën**

*Aan alle deelnemers tijdens de Digestive Disease Days op 20 en 21 maart 2019*

De Nederlandse Vereniging voor Gastroenterologie kent een jarenlange samenwerking met de farmaceutische industrie. De vereniging stelt de farmaceutische industrie in de gelegenheid aanwezig te zijn bij de wetenschappelijke vergaderingen met een stand. Mede hierdoor kan de vereniging haar wetenschappelijke bijeenkomsten organiseren.

De Geneesmiddelenwet zegt dat - onder strikte voorwaarden - de farmaceutische industrie alleen reclame mag maken voor receptgeneesmiddelen voor personen die bevoegd zijn om dergelijke geneesmiddelen voor te schrijven. Alle andere personen (inclusief bijvoorbeeld verpleegkundigen, endoscopie-assistenten en biochemici) worden beschouwd als “publiek”. De farmaceutische industrie mag geen reclame maken voor receptgeneesmiddelen voor publiek.

De Nederlandse Vereniging voor Gastroenterologie is een wetenschappelijke vereniging voor personen die beroepsmatig betrokken zijn bij zorg, onderwijs en onderzoek ten behoeve van patiënten met maag-, darm- en leveraandoeningen. Dat betekent dat ook personen die geen arts zijn, lid van de NVGE zijn.

De aanwezigheid van artsen, niet-artsen en farmaceutische industrieën tijdens het congres kan de NVGE ongewild in aanraking brengen met de inspectie voor de gezondheidszorg, sectie reclametoezicht, en daarmee in diskrediet worden gebracht. Dat willen wij uiteraard voorkomen.

In verband met de Gedragscode Geneesmiddelenreclame van de CGR en de aan het NVGE-congres verbonden expositie van farmaceutische producten, medische instrumenten en voedingsmiddelen, zal bij uw congresregistratie via de NVGE-website worden gevraagd naar uw bevoegdheid om medicijnen voor te schrijven.

Alle congresdeelnemers dragen verplicht een congresbadge waarop behalve de naam ook beroep / functie staat aangegeven. Farmaceutische standhouders benaderen uitsluitend congresdeelnemers die de bevoegdheid hebben om receptgeneesmiddelen voor te schrijven of ter hand te stellen. Om dit extra te verduidelijken zal wederom worden gekozen voor verschillende kleuren congresbadges.

Uit het bovenstaande volgt dat aanwezige reclame-uitingen en merkproductinformatie van farmaceutische industrieën alleen gericht zijn op personen die bevoegd zijn om de betreffende geneesmiddelen voor te schrijven. Wij maken u erop attent dat het voor niet-artsen dan ook niet is toegestaan de stands van de aanwezige farmaceutische industrieën te bezoeken.

De NVGE en farmaceutische industrie (sponsors) vertrouwen erop u met bovenstaande voldoende te hebben geïnformeerd.

Het bestuur van de NVGE

---

**Post ECCO****Brabantzaal**

---

**Voorzitter:** A.E. van der Meulen

- 10.00 Nieuws in de IBD Immunologie  
*Dr. C.S. Horjus, MDL-arts, Rijnstate Ziekenhuis, Arnhem*
- 10.15 Update Fase II en III trials M. crohn en colitis ulcerosa  
*Dr. M. Löwenberg, MDL-arts, Amsterdam UMC (loc. AMC), Amsterdam*
- 10.30 Nieuws huidige IBD medicatie  
*Dr. P.W.J. Maljaars, MDL-arts, LUMC, Leiden*
- 10.45 Update kanker risico in de IBD patiënt  
*Dr. B. Oldenburg, MDL-arts, UMCU, Utrecht*
- 11.00 Nieuws over het microbiom  
*Prof. dr. R.K. Weersma, MDL-arts, UMCG, Groningen*
- 11.15 Ledenvergadering sectie IBD
- 11.30 Ledenvergadering en uitreikingen subsidies NVGE in Baroniezaal

---

**NVGE symposium****Brabantzaal**

---

**Voorzitters :** B.G.P. Koot en P.B.F. Mensink

**Symposium: Jong gekregen, oud gehouden**

- 13.00 'Gastro-oesofageale reflux; van wieg tot graf'  
*Dr. M.P. van Wijk, kinderarts-MDL, Amsterdam UMC, (loc. VUmc), Amsterdam*  
*Prof. dr. A.J.P.M. Smout, MDL-arts, Amsterdam UMC, (loc. AMC), Amsterdam*
- 13.40 Transitiezorg voor patiënten met fecale incontinentie.  
*Dr. M. Groeneweg, kinderarts-MDL, Maasstad Ziekenhuis, Rotterdam*  
*Dr. C.I.M. Baeten, chirurg, Groene Hart Ziekenhuis, Gouda*  
*A.M.C. Baven-Pronk, MDL-arts, Groene Hart Ziekenhuis, Gouda*
- 14.20 Cystic fibrosis, ziektebeeld in transitie: van pancreasenzymen naar colon carcinoom screening.  
*Dr. F.A.J.A. Bodewes, kinderarts-MDL, UMCG, Groningen*  
*C. Hoge, MDL-arts, MUMC, Maastricht*
- 15.00 Theepauze expositiehal

**Voorzitters :** *P.D. Siersema en W.H. de Vos tot Nederveen Cappel*

**Symposium: Op het grensvlak van pathologie en endoscopie**

**Slokdarm**

- 15.30      Introductie casus door aios
- 15.35      De endoscopische behandeling van een vroegcarcinoom in de oesophagus.  
*Dr. R.E. Pouw, MDL-arts, Amsterdam UMC (loc. AMC), Amsterdam*
- 15.45      Commentaar  
*Prof. dr. I. Nagtegaal, patholoog, Radboudumc, Nijmegen*
- 15.50      Discussie + Uitkomst casus aios

**Maag**

- 16.00      Introductie casus door aios
- 16.05      Het vroegcarcinoom: onderschat en overschat  
*Dr. A.D. Koch, MDL-arts, Erasmus MC, Rotterdam*
- 16.15      Commentaar  
*Prof. dr. I. Nagtegaal, patholoog, Radboudumc, Nijmegen*
- 16.20      Discussie + Uitkomst casus aios

**Colon IT**

- 16.30      Introductie casus door aios
- 16.35      De endoscopische behandeling van een TI in het colon  
*Dr. L.M.G. Moons, MDL-arts, UMCU, Utrecht*
- 16.45      Commentaar  
*Prof. dr. I. Nagtegaal, patholoog, Radboudumc, Nijmegen*
- 16.50      Discussie + Uitkomst casus aios

**Colon IBD dysplasie**

- 17.00      Introductie casus door aios
- 17.05      IBD gerelateerde dysplasie  
*Dr. A.C. de Vries, MDL-arts, Erasmus MC, Rotterdam*
- 17.15      Commentaar  
*Prof. dr. I. Nagtegaal, patholoog, Radboudumc, Nijmegen*
- 17.20      Discussie + Uitkomst casus aios

---

**President Select****Brabantzaal**

---

**Voorzitters :** P.D. Siersema en C.J. van der Woude

- 17.30 How to recognize acute on chronic liver failure: tips for the attending physician  
*Prof. dr. J. Wendon, Kings College Hospital, Institute of Liver Sciences, London*
- 18.00 Robot-assisted pancreatoduodenectomy in the Netherlands: a multicenter analysis of the first 100 procedures  
*C.L.M.A. Nota<sup>1</sup>, J. Hagendoorn<sup>1</sup>, M.J.W. Zwart<sup>2</sup>, I.H.M. Borel Rinkes<sup>1</sup>, P.P.L.O. Coene<sup>3</sup>, E.W. van der Harst<sup>3</sup>, W.W. te Riele<sup>4</sup>, T. Tran<sup>5</sup>, H.C. van Santvoort<sup>4</sup>, B. Groot Koerkamp<sup>5</sup>, I.Q. Molenaar<sup>1</sup>.  
<sup>1</sup>Dept. of Gastrointestinal Surgery, UMC Utrecht, Utrecht. <sup>2</sup>Dept. of Gastrointestinal Surgery, Amsterdam UMC (loc. AMC), Amsterdam. <sup>3</sup>Dept. of Gastrointestinal Surgery, Maastad Hospital, Rotterdam. <sup>4</sup>Dept. of Gastrointestinal Surgery, St. Antonius Hospital, Nieuwegein. <sup>5</sup>Dept. of Gastrointestinal Surgery, Erasmus MC, Rotterdam, The Netherlands.*
- 18.10 Early endoscopic retrograde cholangiography with biliary sphincterotomy or conservative treatment in predicted severe acute biliary pancreatitis (apec): a multicenter randomized controlled trial  
*N.J. Schepers<sup>1,2</sup>, N.D.L. Hallensleben<sup>2</sup>, M.G.H. Besselink<sup>3</sup>, M.P.G.F. Anten<sup>2</sup>, T.L. Bollen<sup>4</sup>, F. van Delft<sup>2</sup>, H.M. van Dullemen<sup>2</sup>, M.G.W. Dijkgraaf<sup>2</sup>, C.H.J. van Eijck<sup>2</sup>, G.W. Erkelens<sup>2</sup>, N.S. Erler<sup>5</sup>, P. Fockens<sup>2</sup>, E.J.M. van Geenen<sup>2</sup>, H.G. Gooszen<sup>2</sup>, J. van Grinsven<sup>3</sup>, J.E. van Hooft<sup>2</sup>, R.W.M. van der Hulst<sup>2</sup>, J.M. Jansen<sup>2</sup>, F.J.G.M. Kubben<sup>2</sup>, S.D. Kuiken<sup>2</sup>, R. Laheij<sup>2</sup>, R. Quispel<sup>2</sup>, R.J.J. de Ridder<sup>2</sup>, M.C.M. Rijk<sup>2</sup>, T.E.H. Romkens<sup>2</sup>, C.H.M. Ruigrok<sup>2</sup>, E.J. Schoon<sup>6</sup>, M.P. Schwartz<sup>2</sup>, B.W.M. Spanier<sup>2</sup>, A.C.I.T.L Tan<sup>2</sup>, W.J. Thijs<sup>2</sup>, R. Timmer<sup>2</sup>, N.G. Venneman<sup>2</sup>, R.C. Verdonk<sup>2</sup>, F.P. Vleggaar<sup>2</sup>, W. van de Vrie<sup>2</sup>, B.J. Witteman<sup>2</sup>, H.C. van Santvoort<sup>2</sup>, O.J. Bakker<sup>2</sup>, M.J. Bruno<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Gastroenterology and Hepatology, <sup>3</sup>Dept. of Surgery<sup>4</sup>. Dept. of Radiology, <sup>5</sup>Dept. of Clinical Epidemiology, Erasmus University Medical Center, The Netherlands. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Catharina Ziekenhuis, Eindhoven, The Netherlands. <sup>7</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands.*
- 18.20 Miltefosine decreases visceral hypersensitivity through modulation of the gut microbiome and mycobiome in a rodent model of Irritable Bowel Syndrome  
*I.A.M. van Thiel<sup>1</sup>, S. Botschuijver<sup>1</sup>, S.A. van Diest<sup>1</sup>, T.B.M. Hakvoort<sup>1</sup>, F.H.J. Schuren<sup>2</sup>, W.J. de Jonge<sup>1</sup>, R.M. van den Wijngaard<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology, Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC (loc. AMC), Amsterdam. <sup>2</sup>Dept. of Microbiology and Systems Biology, The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands.*

---

**Uitreiking prijzen****Brabantzaal**

---

**Voorzitters :** P.D. Siersema en C.J. van der Woude

- 18.30 Uitreiking NVGE Gastrointestinale Research Award 2019  
Gevolgd door voordracht door de prijswinnaar
- 18.45 Congresborrel
- 19.30 Diner in de Beneluxzaal

Woensdag 20 maart 2019

---

**Nederlandse Vereniging voor Hepatologie****Auditorium**

---

09.30 Ledenvergadering NVH

---

**Symposium – Nederlandse Vereniging voor Hepatologie****Auditorium**

---

**Voorzitters :** *J.I. Erdmann en J.M. Vrolijk*

**Symposium: Do's en don'ts van chirurgie bij levercirrose**

- 10.00 Een hepatologische kijk op leverfunctie, leverfalen en mortaliteit bij leverchirurgie  
*Prof. dr. H.J. Metselaar, MDL-arts, Erasmus MC, Rotterdam*
- 10.20 Een chirurgische kijk op leverfunctie, leverfalen en mortaliteit bij leverchirurgie  
*Dr. J.I. Erdmann, chirurg, Amsterdam UMC (loc. AMC), Amsterdam*
- 10.40 Consequenties van operaties anders dan leveroperaties bij patiënten met cirrose  
*Prof. dr. G. Kazemier, chirurg, Amsterdam UMC (loc. VUmc), Amsterdam*
- 11.00 En erna? Postoperatieve zorg bij patiënten met levercirrose  
*Dr. C.M. den Hoed, MDL-arts, Erasmus MC, Rotterdam*
- 11.30 Ledenvergadering NVGE in Baroniezaal
- 12.00 Lunch expositiehal

---

**Symposium – Sectie Gastrointestinale Endoscopie****Auditorium**

---

**Voorzitters :** *M.J.M. Groenen en L.M.G. Moons*

**Thema: Future in Endoscopy**

- 13.00 Future Aspects in Barrett's Esophagus  
*Prof. dr. B.L.A.M. Weusten, MDL-arts, UMCU, Utrecht*
- 13.30 Molecular Imaging in Endoscopy  
*Dr. W.B. Nagengast, MDL-arts, UMCG, Groningen*
- 13.50 Artificial Intelligence in optical diagnosis  
*Dr. E.J. Schoon, MDL-arts, Catharina ziekenhuis, Eindhoven*
- 14.10 Future Aspects in ERCP  
*Dr. A. Inderson, MDL-arts, LUMC, Leiden*
- 14.30 Future in Endoscopy  
*Spreker volgt*
- 15.00 Pauze

Woensdag 20 maart 2019

---

**Symposium – Nederlandse Vereniging van Maag-Darm-Leverartsen****Auditorium**

---

**Voorzitters :** n.t.b.

**Symposium: Opioiden gebruik en misbruik**

- 15.30 De stille opioïd epidemie!
- 15.55 Opioid gebruik bij chronische buikpijn: misconcepties en misvattingen
- 16.20 Narcotic bowel syndroom
- 16.45 Het moet beter, maar hoe?
- 17.10 Ervaringen in de MDL praktijk: casuïstiek
- 17.30 Plenaire sessie in de Brabantzaal
- 18.45 Congresborrel
- 19.30 Diner in de Beneluxzaal

---

**Meet the expertsessie****Baroniezaal**

---

**Thema: Pancreascarcinoom**

10.00 – 11.00

*Deze sessie – waarvoor tevoren moet worden ingeschreven - wordt verzorgd door:*

*Prof. dr. M.J. Bruno, MDL-arts, Erasmus MC, Rotterdam  
Dr. M.B.S. Stommel, HPB chirurg, Radboudumc, Nijmegen*

---

**Ledenvergadering NVGE****Baroniezaal**

---

**Voorzitter:** P.D. Siersema

- 11.30 Ledenvergadering Nederlandse Vereniging voor Gastroenterologie
- 12.00 Lunch expositiehal



**Voorzitters :** A.G.L. Bodelier en B. Oldenburg

- 13.00 In-depth characterization of host-genetics and gut microbiome unravels novel host-microbiome interactions in inflammatory bowel disease  
S. Hu<sup>1</sup>, A. Vich Vila<sup>1</sup>, R. Gacesa<sup>1</sup>, V. Collij<sup>1</sup>, R.J. Xavier<sup>2</sup>, C. Stevens<sup>3</sup>, M.J. Daly<sup>3</sup>, C. Wijmenga<sup>4</sup>, H. van Dullemen<sup>1</sup>, G. Dijkstra<sup>1</sup>, M.C. Visschedijk<sup>1</sup>, E. Festen<sup>1</sup>, J. Fu<sup>5</sup>, A. Kurilshikov<sup>4</sup>, A. Zhernakova<sup>4</sup>, R. Weersma<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen, The Netherlands. <sup>2</sup>Dept. of Gastroenterology, Massachusetts General Hospital, Boston, United States of America. <sup>3</sup>Dept. of Clinical Genetics, Broad Institute, Boston, United States of America. <sup>4</sup>Dept. of Clinical Genetics, UMC Groningen, Groningen, The Netherlands. <sup>5</sup>Dept. of Pediatrics, UMC Groningen, Groningen, The Netherlands.
- 13.10 Combining absolute quantification of fecal bacteria with metagenomic sequencing data improves the characterization of the gut microbiome of patients with Crohn's disease  
A. Vich Vila<sup>1</sup>, A.M. Boddeke<sup>1</sup>, A. Kurilshikov<sup>2</sup>, J.Z.H.V.O Martels<sup>1</sup>, V. Collij<sup>1</sup>, P. Sureda Horrach<sup>1</sup>, A.R. Bourgonje<sup>1</sup>, S. Hu<sup>1</sup>, A. Zhernakova<sup>2</sup>, G. Dijkstra<sup>1</sup>, H.J.M. Harmsen<sup>3</sup>, R.K. Weersma<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Clinical Genetics, <sup>3</sup>Dept. of Medical Microbiology, UMC Groningen, Groningen, The Netherlands.
- 13.20 Detection and monitoring of IBD based on faecal volatile organic compounds  
S. Bosch<sup>1</sup>, D. Wintjens<sup>2</sup>, A. Wicaksono<sup>3</sup>, J. Kuijvenhoven<sup>4</sup>, R. van der Hulst<sup>4</sup>, P. Stokkers<sup>5</sup>, E. Daulton<sup>3</sup>, M. Pierik<sup>2</sup>, J.A. Covington<sup>3</sup>, T.G.J. de Meij<sup>6</sup>, K.H.N. de Boer<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, The Netherlands. <sup>3</sup>School of Engineering, University of Warwick, Coventry, United Kingdom. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Spaarne Gasthuis, Hoofddorp/Haarlem, The Netherlands. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis West, Amsterdam, The Netherlands. <sup>6</sup>Dept. of Pediatrics, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands.
- 13.30 Therapeutic drug monitoring in ustekinumab: which factors affect trough levels?  
R. Theeuwes<sup>1</sup>, N. Provoost<sup>2</sup>, C.A.M. de Koning<sup>2</sup>, A. van der Meulen-de Jong<sup>2</sup>, D.J.A. Moes<sup>3</sup>, J. Maljaars<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology, <sup>2</sup>Dept. of Gastroenterology and Hepatology, <sup>3</sup>Dept. of Clinical Pharmacy and Toxicology, Leiden UMC, Leiden, The Netherlands.
- 13.40 Higher discontinuation rates of anti-TNF therapy in elderly IBD patients compared to a younger age group: results from a prospective registry  
L.J.T. Smits<sup>1</sup>, M.E. de Jong<sup>2</sup>, N. den Broeder<sup>1</sup>, M.G.V.M. Russel<sup>3</sup>, T.E.H. Römkens<sup>4</sup>, R.L. West<sup>5</sup>, J.M. Jansen<sup>6</sup>, F. Hoentjen<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen. <sup>2</sup>Dept. of Gastroenterology, Radboudumc, Nijmegen. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
- 13.50 Premedication with steroids does not influence the incidence of Infusion Reactions after Infliximab Infusions in paediatric IBD patients - a retrospective case-control study.  
E.A. van Wassenaer<sup>1</sup>, V.L. Meester<sup>2</sup>, A. Kindermann<sup>1</sup>, B.G.P. Koot<sup>1</sup>, M.A. Benninga<sup>1</sup>, T.G.J. de Meij<sup>2</sup>. <sup>1</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Emma Children's Hospital, Amsterdam UMC, Amsterdam. <sup>2</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands.

- 14.00 Prevalence of cervical dysplasia in women with Inflammatory Bowel Disease: data from the Parelsoer Institute (PSI) and PALGA database (PAP-IBD study)  
R.L. Goetgebuuer<sup>1</sup>, J.E. Kreijne<sup>1</sup>, C.A. Aitken<sup>2</sup>, M.J. Pierik<sup>3</sup>, F. Hoentjen<sup>4</sup>, N.K. de Boer<sup>5</sup>, B. Oldenburg<sup>6</sup>, A.E. van der Meulen<sup>7</sup>, C.I.J. Ponsioen<sup>8</sup>, G. Dijkstra<sup>9</sup>, F.A. van Kemenade<sup>10</sup>, G.M. Nieuwenhuijzen-de Boer<sup>11</sup>, A.G. Siebers<sup>12</sup>, C.J. van der Woude<sup>1</sup>, A.C. de Vries<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>2</sup>Dept. of Public Health, Erasmus MC, Rotterdam. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. VUmc), Amsterdam. <sup>6</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht. <sup>7</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden. <sup>8</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam. <sup>9</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen. <sup>10</sup>Dept. of Pathology, Erasmus MC, Rotterdam. <sup>11</sup>Dept. of Gynaecological Oncology, Erasmus MC, Rotterdam. <sup>12</sup>Dept. of Biomedical Data Sciences, Palga, the nationwide network and registry of histo- and cytopathology in NL, Houten, The Netherlands.
- 14.10 Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia  
M.E. de Jong<sup>1</sup>, H. Kanne<sup>1</sup>, L.H.C. Nissen<sup>2</sup>, I.D. Nagtegaal<sup>3</sup>, J.P.H. Drenth<sup>1</sup>, L.A.A.P. Derikx<sup>1</sup>, F. Hoentjen<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Hospital, s' Hertogenbosch. <sup>3</sup>Dept. of Pathology, Radboudumc, Nijmegen, The Netherlands.
- 14.20 Environmental and lifestyle factors are associated with a divergent effect on the course of Inflammatory Bowel Diseases  
H.C. Rijkman<sup>1</sup>, K.W.J. van der Sloot<sup>1</sup>, M.C. Visschedijk<sup>1</sup>, E.A.M. Festen<sup>1</sup>, H.M. van Dullemen<sup>1</sup>, R.K. Weersma<sup>1</sup>, B.Z. Alizadeh<sup>2</sup>, G. Dijkstra<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Epidemiology, UMC Groningen, Groningen, The Netherlands.
- 14.32 Treatment of perianal fistulas in Crohn's disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trial  
K.A.T.G.M. Wasmann<sup>1</sup>, E.J. de Groof<sup>1</sup>, M.E. Stellingwerf<sup>1</sup>, G.R.A.M. D'Haens<sup>2</sup>, C.Y. Ponsioen<sup>2</sup>, K.B. Gecse<sup>2</sup>, M.G.W. Dijkgraaf<sup>3</sup>, W.A. Bemelman<sup>1</sup>, C.J. Buskens<sup>1</sup>. <sup>1</sup>Dept. of Surgery, <sup>2</sup>Dept. of Gastroenterology and Hepatology, <sup>3</sup>Dept. of Epidemiology, Amsterdam UMC, The Netherlands.
- 14.42 Prediction of endoscopic activity in patients with Crohn's disease - systematic review and external validation of published prediction models  
E.C. Brand<sup>1</sup>, S.G. Elias<sup>2</sup>, I.M. Minderhoud<sup>3</sup>, J.J. van der Veen<sup>1</sup>, F.J. Baert<sup>4</sup>, D. Laharie<sup>5</sup>, P. Bossuyt<sup>6</sup>, Y. Bouhnik<sup>7</sup>, A. Buisson<sup>8</sup>, G. Lambrecht<sup>9</sup>, E. Louis<sup>10</sup>, B. Pariente<sup>11</sup>, M.J. Pierik<sup>12</sup>, C.J. van der Woude<sup>13</sup>, G.R.A.M. D'Haens<sup>14</sup>, S. Vermeire<sup>15</sup>, B. Oldenburg<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands. <sup>2</sup>Dept. of Clinical Epidemiology, UMC Utrecht, Utrecht, The Netherlands. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Tergooi Hospitals, Blaricum/Hilversum, The Netherlands. <sup>4</sup>Dept. of Gastroenterology, AZ Delta, Roeselare, Belgium. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Hôpital Haut-Lévêque, Bordeaux, France. <sup>6</sup>Dept. of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium. <sup>7</sup>Dept. of Gastroenterology, Beaujon Hospital, APHP, Paris Diderot University, Clichy, France. <sup>8</sup>Dept. of Gastroenterology, Estaing University Hospital, Clermont-Ferrand, France. <sup>9</sup>Dept. of Gastroenterology, AZ Damiaan, Oostende, Belgium. <sup>10</sup>Dept. of Gastroenterology, Liège University Hospital CHU, Liège, France. <sup>11</sup>Dept. of Gastroenterology, Huriez Hospital, Lille 2 University, Lille, France. <sup>12</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, The Netherlands. <sup>13</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands. <sup>14</sup>Dept. of Gastroenterology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. <sup>15</sup>Dept. of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
- 15.00 Theepauze

**Voorzitters :** L.J.A.C. Hawinkels en M. Pierik

- 15.30 Inleiding  
L.J.A.C. Hawinkels
- 15.40 Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC Case Series, a nationwide prospective observational cohort study  
V.B.C. Biemans<sup>1</sup>, C.J. van der Woude<sup>2</sup>, G. Dijkstra<sup>3</sup>, A.E. van der Meulen-de Jong<sup>4</sup>, B. Oldenburg<sup>5</sup>, N.K.H. de Boer<sup>6</sup>, M. Löwenberg<sup>7</sup>, N. Srivastava<sup>8</sup>, J.M. Jansen<sup>9</sup>, R. West<sup>10</sup>, A.C. de Vries<sup>2</sup>, J.J.L. Haans<sup>11</sup>, M.J. Pierik<sup>11</sup>, F. Hoentjen<sup>12</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>3</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden. <sup>5</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. VUmc), Amsterdam. <sup>7</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam. <sup>8</sup>Dept. of Gastroenterology and Hepatology, Haaglanden MC, Den Haag. <sup>9</sup>Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam. <sup>10</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam. <sup>11</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht. <sup>12</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands.
- 15.50 Acetylcholine secreting T-cells contribute to innate immune driven colitis  
R.A. Willemze, D.J. Brinkman, O. Welting, H.P. van Hamersveld, M.E. Wildenberg, J. Seppen, W.J. de Jonge. Dept. of Gastroenterology, Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands.
- 16.02 High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease  
L.F. Ouboter<sup>1</sup>, V. van Unen<sup>2</sup>, N. Li<sup>2</sup>, T. Abdelaal<sup>3</sup>, Y. Kooy-Winkelaar<sup>2</sup>, G. Beyrend<sup>2</sup>, T. Höllt<sup>4</sup>, M.L. Mearin<sup>5</sup>, A.M.C. Witte<sup>6</sup>, J.C. Escher<sup>7</sup>, B.P.F. Lelieveldt<sup>8</sup>, A.E. van der Meulen-de Jong<sup>9</sup>, F. Koning<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden. <sup>2</sup>Dept. of Immunohematology and Blood Transfusion, Leiden UMC, Leiden. <sup>3</sup>Delft Bioinformatics Lab, Delft University of Technology, Delft. <sup>4</sup>Computer Graphics and Visualization, Delft University of Technology, Delft. <sup>5</sup>Dept. of Pediatrics, Leiden UMC, Leiden. <sup>6</sup>Dept. of Gastroenterology, Alrijne Hospital, Leiderdorp. <sup>7</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Erasmus MC, Rotterdam. <sup>8</sup>Dept. of LKEB Radiology, Leiden UMC, Leiden. <sup>9</sup>Dept. of Gastroenterology, Leiden UMC, Leiden, The Netherlands.
- 16.14 Exosomes derived from mesenchymal stromal cells enhance epithelial regeneration in vitro and in experimental colitis induced by DSS in mice  
L.G. Plug<sup>1</sup>, M.C. Barnhoorn<sup>1</sup>, E.S.M. de Jonge-Muller<sup>1</sup>, E. Bos<sup>2</sup>, A.E. van der Meulen-de Jong<sup>1</sup>, H.W. Verspaget<sup>1</sup>, L.J.A.C. Hawinkels<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Cell and Chemical Biology, Leiden UMC, Leiden, The Netherlands.
- 16.26 Dashboard driven dosing of infliximab is superior to conventional treatment in inflammatory bowel disease: the PRECISION trial  
A.S. Strik<sup>1</sup>, S.E. Berends<sup>2</sup>, D.R. Mould<sup>3</sup>, R.A. Mathot<sup>2</sup>, C.I. Ponsioen<sup>1</sup>, J. van den Brande<sup>4</sup>, J. Jansen<sup>5</sup>, D.R. Hoekman<sup>6</sup>, J.F. Brandse<sup>7</sup>, M. Lowenberg<sup>1</sup>, G.R. D'Haens<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands. <sup>2</sup>Dept. of Hospital Pharmacy, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands. <sup>3</sup>Dept. of Hospital Pharmacy, Projections Research Inc., Phoenixville, United States of America. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Tergooi Hospital, Hilversum, The Netherlands. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.

<sup>6</sup>Dept. of Clinical Genetics, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands. <sup>7</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands.

- 16.38 Faecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab  
R.W.M. Pauwels<sup>1</sup>, A.C. de Vries<sup>1</sup>, J.C. Goet<sup>1</sup>, N.S. Erler<sup>2</sup>, C.J. van der Woude<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Biomedical Data Sciences, Erasmus MC, Rotterdam, The Netherlands.
- 16.50 Prediction model to safely cease anti-TNF therapy in Crohn's disease: individual patient data meta-analysis (IPD-MA)  
R.W.M. Pauwels<sup>1</sup>, C.J. van der Woude<sup>1</sup>, D. Nieboer<sup>2</sup>, E.W. Steyerberg<sup>3,12</sup>, M.J. Casanova<sup>4</sup>, J.P. Gisbert<sup>4</sup>, A.J. Lobo<sup>5</sup>, C.W. Lees<sup>6</sup>, N.A. Kennedy<sup>6</sup>, T. Molnár<sup>7</sup>, K. Szántó<sup>7</sup>, E. Louis<sup>8</sup>, J.Y. Mary<sup>9</sup>, M. Lukas<sup>10,13</sup>, M. Duijvestein<sup>11</sup>, S. Bots<sup>11</sup>, G.R.A.M. D'Haens<sup>11</sup>, A.C. de Vries<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands. <sup>2</sup>Dept. of Health Services Research, Erasmus MC, Rotterdam, The Netherlands. <sup>3</sup>Dept. of Biomedical Data Sciences, Leiden UMC, Leiden, The Netherlands. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Madrid Hospital Universitario de la Princesa, Madrid, Spain. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Western General Hospital, Edinburgh, United Kingdom. <sup>7</sup>Dept. of Internal Medicine, University of Szeged, Szeged, Hungary. <sup>8</sup>Dept. of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Liège, Liège, France. <sup>9</sup>Dept. of Biomedical Data Sciences, Inserm U717, Paris, France. <sup>10</sup>Dept. of Gastroenterology and Hepatology, IBD Clinical and Research Centre, Prague, Czech Republic. <sup>11</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands. <sup>12</sup>Dept. of Public Health, Erasmus MC, The Netherlands. <sup>13</sup>Institute of Medical Biochemistry and Laboratory Diagnostics, 1<sup>st</sup> Medical Faculty and General Teaching Hospital, Prague, Czech Republic.
- 17.00 The cytokine milieu in patients with Inflammatory Bowel Disease impacts the phenotype of mesenchymal stromal cells  
M.C. Barnhoorn<sup>1</sup>, K. Schepers<sup>2</sup>, H.W. Verspaget<sup>1</sup>, W. Fibbe<sup>2</sup>, L.J.A.C. Hawinkels<sup>1</sup>, M. van Pel<sup>2</sup>, A.E. van der Meulen-de Jong<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Immunohematology and Blood Transfusion, Leiden UMC, Leiden, The Netherlands.
- 17.03 PNA<sup>+</sup> and MAdCAM<sup>+</sup> High Endothelial Venules correlate with disease activity in ulcerative colitis  
B. Roosenboom<sup>1</sup>, C.S. Horjus Talabur Horje<sup>1</sup>, M.J.M. Groenen<sup>1</sup>, C. Smids<sup>1</sup>, J. Meijer<sup>2</sup>, E.G. van Lochem<sup>3</sup>, P.J. Wahab<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Pathology, <sup>3</sup>Dept. of Immunopathology, Rijnstate Hospital, Arnhem, The Netherlands.
- 17.15 Mucosal macrophages express elevated levels of HDAC9 in inflamed and uninfamed mucosa of Crohn's disease, but not ulcerative colitis  
M. Ghiboub<sup>1</sup>, J. de Bruyn<sup>1</sup>, C. Wichers<sup>2</sup>, T. Radstake<sup>2</sup>, K. Reedquist<sup>2</sup>, M.E. Wildenberg<sup>1</sup>, J. Broen<sup>2</sup>, G. D'Haens<sup>3</sup>, W. de Jonge<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology, Amsterdam UMC (loc. AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam. <sup>2</sup>Dept. of Immunopathology, Utrecht UMC, Utrecht. <sup>3</sup>Dept. of Gastroenterology, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands.
- 17.30 Plenaire sessie in de Brabantzaal
- 18.45 Congresborrel in de expositiehal
- 19.30 Diner in de Beneluxzaal

**Thema: IgG gemedieerde ziekte**

10.00 – 11.00

Deze sessie – waarvoor tevoren moet worden ingeschreven - wordt verzorgd door

Prof. dr. U.H.W. Beuers, MDL-arts, Amsterdam UMC (loc. AMC), Amsterdam

Dr. H.R. van Buuren, MDL-arts, Erasmus MC, Rotterdam

---

**Abstractsessie - Sectie Gastrointestinale Oncologie**

**Parkzaal**

---

**Voorzitters :** V.M.C.W. Spaander en N. van Lelyveld

- 13.00 Prognostic factors and survival in MEN1 patients with gastrinomas: results from the DutchMEN Study Group (DMSG)  
D.J. van Beek<sup>1</sup>, S. Nell<sup>1</sup>, C.R.C. Pieterman<sup>2</sup>, W.W. de Herder<sup>2</sup>, A.C. van de Ven<sup>2</sup>, O.M. Dekkers<sup>3</sup>, A.N. van der Horst-Schrivers<sup>2</sup>, M.L. Drent<sup>2</sup>, P.H. Bisschop<sup>2</sup>, B. Havekes<sup>2</sup>, I.H.M. Borel Rinkes<sup>1</sup>, M.R. Vriens<sup>1</sup>, G.D. Valk<sup>2</sup>. <sup>1</sup>Dept. of Gastrointestinal Surgery, <sup>2</sup>Dept. of Internal Medicine, <sup>3</sup>Dept. of Epidemiology, UMC Utrecht, Utrecht, The Netherlands.
- 13.10 Endoscopically removed colorectal NETs; a nationwide cohort study  
T. Kuiper<sup>1</sup>, M.G.H. van Oijen<sup>2</sup>, M.L. van Velthuisen<sup>3</sup>, N. van Lelyveld<sup>4</sup>, M. van Leerdam<sup>5</sup>, F.D. Vleggaar<sup>1</sup>, H.J. Klumpen<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology, UMC Utrecht, Utrecht. <sup>2</sup>Dept. of Gastrointestinal Oncology, Amsterdam UMC, Amsterdam. <sup>3</sup>Dept. of Pathology, Erasmus MC, Rotterdam. <sup>4</sup>Dept. of Gastroenterology, St Antonius Hospital, Nieuwegein. <sup>5</sup>Dept. of Gastroenterology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
- 13.20 Effect of perioperative treatment on microsatellite instable gastric cancer in the CRITICS trial  
H.D. Biesma<sup>1</sup>, K. Sikorska<sup>2</sup>, D. Hoek<sup>1</sup>, H.F. van Essen<sup>1</sup>, B. Ylstra<sup>1</sup>, E. Meershoek-Klein Kranenbarg<sup>3</sup>, C.J.H. van de Velde<sup>3</sup>, H.W.M. van Laarhoven<sup>4</sup>, J.W. van Sandick<sup>5</sup>, M. Nordmark<sup>6</sup>, M.L. Jespersen<sup>7</sup>, M. Verheij<sup>8</sup>, A. Cats<sup>9</sup>, N.C.T. van Grieken<sup>1</sup>. <sup>1</sup>Dept. of Pathology, Cancer Center Amsterdam - Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands. <sup>2</sup>Dept. of Biometrics, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. <sup>3</sup>Dept. of Surgery, Leiden UMC, Leiden, The Netherlands. <sup>4</sup>Dept. of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. <sup>5</sup>Dept. of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. <sup>6</sup>Dept. of Medical Oncology, Aarhus University Hospital, Aarhus, Denmark. <sup>7</sup>Dept. of Pathology, Aarhus University Hospital, Aarhus, Denmark. <sup>8</sup>Dept. of Radiotherapy, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. <sup>9</sup>Dept. of Gastroenterology and Hepatology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- 13.30 A comparison of elderly versus non-elderly patients in the CRITICS gastric cancer trial  
A.E. Slagter<sup>1</sup>, B. Tudela<sup>2</sup>, R.M. van Amelsfoort<sup>1</sup>, K. Sikorska<sup>3</sup>, J.W. van Sandick<sup>4</sup>, C.J.H. van de Velde<sup>5</sup>, N.C.T. van Grieken<sup>6</sup>, P. Lind<sup>7</sup>, M. Nordmark<sup>8</sup>, H. Putter<sup>9</sup>, C. Grootsholten<sup>10</sup>, E. Meershoek-Klein Kranenbarg<sup>5</sup>, E.P.M. Jansen<sup>1</sup>, A. Cats<sup>11</sup>, M. Verheij<sup>12</sup>. <sup>1</sup>Dept. of Radiation Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. <sup>2</sup>Dept. of Radiation Oncology, Universidad de Valparaíso, Valparaíso, Chile. <sup>3</sup>Dept. of Biostatistics, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. <sup>4</sup>Dept. of Surgery, Antoni van Leeuwenhoek,

Amsterdam, The Netherlands. <sup>5</sup>Dept. of Surgery, Leiden UMC, Leiden, The Netherlands. <sup>6</sup>Dept. of Pathology, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands. <sup>7</sup>Dept. of Medical Oncology, Karolinska Institutet, Stockholm, Sweden. <sup>8</sup>Dept. of Medical Oncology, Aarhus University Hospital, Aarhus, Denmark. <sup>9</sup>Dept. of Biostatistics, Leiden UMC, Leiden, The Netherlands. <sup>10</sup>Dept. of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. <sup>11</sup>Dept. of Gastrointestinal Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. <sup>12</sup>Dept. of Radiation Oncology, Radboudumc, Nijmegen, The Netherlands.

- 13.40 Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial  
A.E. Slagter<sup>1</sup>, K. Sikorska<sup>2</sup>, C. Grootsholten<sup>3</sup>, H.W.M. van Laarhoven<sup>4</sup>, H. Boot<sup>5</sup>, E. Meershoek-Klein Kranenbarg<sup>6</sup>, C.J.H. van de Velde<sup>6</sup>, N.C.T. van Grieken<sup>7</sup>, E.P.M. Jansen<sup>1</sup>, M. Verheij<sup>8</sup>, A. Cats<sup>5</sup>. <sup>1</sup>Dept. of Radiation Oncology, Antoni van Leeuwenhoek, Amsterdam. <sup>2</sup>Dept. of Biostatistics, Antoni van Leeuwenhoek, Amsterdam. <sup>3</sup>Dept. of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam. <sup>4</sup>Dept. of Medical Oncology, Amsterdam UMC (loc. AMC), Amsterdam. <sup>5</sup>Dept. of Gastrointestinal Oncology, Antoni van Leeuwenhoek, Amsterdam. <sup>6</sup>Dept. of Surgery, Leiden UMC, Leiden. <sup>7</sup>Dept. of Pathology, Amsterdam UMC (loc. VUmc), Amsterdam. <sup>8</sup>Dept. of Radiation Oncology, Radboudumc, Nijmegen, The Netherlands.
- 13.50 Factors associated with the progression of gastric intestinal metaplasia in a low risk population - A multicenter, prospective cohort study  
S.A.V. Nieuwenburg<sup>1</sup>, M.C. Mommersteeg<sup>1</sup>, T.J. Tang<sup>2</sup>, M.P. Anten<sup>3</sup>, I. Prytz-Berset<sup>4</sup>, E. Witteman<sup>5</sup>, F. ten Borg<sup>6</sup>, G.D. den Hartog<sup>7</sup>, M.J. Bruno<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, M. Doukas<sup>8</sup>, E.J. Kuipers<sup>1</sup>, M.C.W. Spaander<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, IJsselland Hospital, Capelle a/d IJssel, The Netherlands. <sup>3</sup>Dept. of Gastroenterology and Hepatology, St. Fransiscus Hospital, Rotterdam, The Netherlands. <sup>4</sup>Dept. of Gastroenterology and Hepatology, More and Romsdal Trust, Alesund, Norway. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Deventer Hospital, Deventer, The Netherlands. <sup>7</sup>Dept. of Gastroenterology and Hepatology, Rijnstate, Arnhem, The Netherlands. <sup>8</sup>Dept. of Pathology, Erasmus MC, Rotterdam, The Netherlands.
- 14.00 Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance  
K.A. Overbeek<sup>1</sup>, D.L. Cahen<sup>1</sup>, A. Kamps<sup>1</sup>, I.C.A.W. Konings<sup>1</sup>, F. Harinck<sup>1</sup>, M.A. Kuenen<sup>2</sup>, B. Groot Koerkamp<sup>3</sup>, M.G.H. Besselink<sup>4</sup>, A. Wagner<sup>5</sup>, M.G.E. Ausems<sup>6</sup>, M. van der Vlugt<sup>7</sup>, P. Fockens<sup>7</sup>, F. Vleggaar<sup>8</sup>, J.W. Poley<sup>1</sup>, J.E. van Hooft<sup>7</sup>, E.M.A. Bleiker<sup>2</sup>, M.J. Bruno<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>2</sup>Dept. of Scientific Research, Netherlands Cancer Institute, Amsterdam. <sup>3</sup>Dept. of Surgery, Erasmus MC, Rotterdam. <sup>4</sup>Dept. of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam. <sup>5</sup>Dept. of Clinical Genetics, Erasmus MC, Rotterdam. <sup>6</sup>Dept. of Clinical Genetics, UMC Utrecht, Utrecht. <sup>7</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam. <sup>8</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands.
- 14.10 12 Years of prospective pancreatic cancer surveillance: results of the Dutch nationwide program in high-risk individuals  
K.A. Overbeek<sup>1</sup>, I.J.M. Levink<sup>1</sup>, I.C.A.W. Konings<sup>1</sup>, F. Harinck<sup>1</sup>, B. Koopmann<sup>1</sup>, M.G.E. Ausems<sup>2</sup>, A. Wagner<sup>3</sup>, P. Fockens<sup>4</sup>, B. Groot Koerkamp<sup>5</sup>, M.G.H. Besselink<sup>6</sup>, M. van der Vlugt<sup>4</sup>, F. Vleggaar<sup>7</sup>, J.W. Poley<sup>1</sup>, D.L. Cahen<sup>1</sup>, J.E. van Hooft<sup>4</sup>, M.J. Bruno<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>2</sup>Dept. of Clinical Genetics, UMC Utrecht, Utrecht. <sup>3</sup>Dept. of Clinical Genetics, Erasmus MC, Rotterdam. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam. <sup>5</sup>Dept. of Surgery, Erasmus MC, Rotterdam. <sup>6</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam. <sup>7</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands.

- 14.20 Yield of malignant lymph node detection by EUS and FNA in restaging after neoadjuvant chemoradiotherapy for esophageal cancer  
R.D. van der Bogt<sup>1</sup>, B.J. van der Wilk<sup>2</sup>, J.W. Poley<sup>1</sup>, K.K. Krishnadath<sup>3</sup>, E.J. Schoon<sup>4</sup>, L.E. Oostenbrug<sup>5</sup>, P.D. Siersema<sup>6</sup>, F.P. Vleggaar<sup>7</sup>, K. Biermann<sup>8</sup>, J.J.B. van Lanschot<sup>2</sup>, M.C.W. Spaander<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>2</sup>Dept. of Surgery, Erasmus MC, Rotterdam. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Zuyderland Medical Center, Heerlen. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen. <sup>7</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht. <sup>8</sup>Dept. of Pathology, Erasmus MC, Rotterdam, The Netherlands.
- 14.30 Genomic biomarkers for cancer risk in Barrett's esophagus: an update on the longitudinal dutch barrett's esophagus cohort  
K.K. Krishnadath<sup>1,3,7</sup>, S.J.M. Hoefnagel<sup>1</sup>, W.M. Westra<sup>1</sup>, M.R. Timmer<sup>1</sup>, P. Martinez<sup>2</sup>, E. Klaver<sup>3</sup>, C.T. Lau<sup>1</sup>, S. Calpe<sup>1</sup>, C.M. del Sancho-Serra<sup>1</sup>, D. Straub<sup>1</sup>, A.M. Baker<sup>2</sup>, A.M. Rygiel<sup>1</sup>, W.D. Rosmolen<sup>3</sup>, S.L. Meijer<sup>5</sup>, F.J.W. ten Kate<sup>5</sup>, M.G.W. Dijkgraaf<sup>7</sup>, R.C. Mallant-Hent<sup>7</sup>, A.H.J. Naber<sup>7</sup>, A.H.A.M. van Oijen<sup>7</sup>, L.C. Blaak<sup>7</sup>, P. Scholten<sup>7</sup>, C.J.M. Böhmer<sup>7</sup>, C.C. Maley<sup>6</sup>, T.A. Graham<sup>2</sup>, J.J.G.H.M. Bergman<sup>3,7</sup>. <sup>1</sup>Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Evolution and Cancer Laboratory, Barts Cancer Institute, London, United Kingdom. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>4</sup>Dept. of Oncogenomics, Amsterdam UMC, Amsterdam, The Netherlands. <sup>5</sup>Dept. of Pathology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>6</sup>Biodesign Institute, School of Life Sciences, Arizona State University, Tempe, United States of America. <sup>7</sup>Gastroenterological Association, Amsterdam, The Netherlands.
- 14.40 Mutational signatures during the preneoplastic cascade towards cholangiocarcinoma in Primary Sclerosing Cholangitis  
E.J.C.A. Kamp<sup>1</sup>, W.N.M. Dinjens<sup>2</sup>, R. van Marion<sup>2</sup>, M. Doukas<sup>2</sup>, J. Verheij<sup>3</sup>, M.J. Bruno<sup>1</sup>, B. Groot Koerkamp<sup>4</sup>, M.P. Peppelenbosch<sup>1</sup>, A.C. de Vries<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>2</sup>Dept. of Pathology, Erasmus MC, Rotterdam. <sup>3</sup>Dept. of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam. <sup>4</sup>Dept. of Surgery, Erasmus MC, Rotterdam, The Netherlands.
- 14.50 Trends in incidence, treatment and survival of gallbladder cancer; a nation-wide cohort study  
E.A.J. de Savornin Lohman<sup>1</sup>, T.J.J. de Bitter<sup>2</sup>, R.H. Verhoeven<sup>3</sup>, L. van der Geest<sup>3</sup>, I.D. Nagtegaal<sup>2</sup>, C.J.H.M. van Laarhoven<sup>1</sup>, J. Hagendoorn<sup>1</sup>, N. Haj Mohammad<sup>5</sup>, F. Daams<sup>1</sup>, H. Klumpen<sup>4</sup>, T.M. van Gulik<sup>1</sup>, J.I. Erdmann<sup>1</sup>, M.T. de Boer<sup>1</sup>, B. Groot Koerkamp<sup>1</sup>, A.E. Braat<sup>1</sup>, R.J. de Haas<sup>5</sup>, P. van der Boezem<sup>1</sup>, R.S. van der Post<sup>2</sup>, P.R. de Reuver<sup>1</sup>. <sup>1</sup>Dept. of Surgery, <sup>2</sup>Dept. of Pathology, Radboudumc, Nijmegen. <sup>3</sup>Integraal Kankercentrum Nederland (IKNL), Utrecht. <sup>4</sup>Dept. of Medical Oncology, UMC Utrecht, Utrecht. <sup>5</sup>Dept. of Radiology and Nuclear Medicine, Groningen UMC, Groningen, The Netherlands.
- 15.00 A Functional Assay-Based Procedure to Classify Mismatch Repair Gene Variants in Lynch Syndrome.  
M. Drost<sup>1</sup>, Y. Tiersma<sup>1</sup>, B.A. Thompson<sup>2,3</sup>, A.B. Spurdle<sup>4</sup>, J.H. Frederiksen<sup>5</sup>, G. Keijzers<sup>5</sup>, L. Pappas<sup>6</sup>, K.M. Boucher<sup>6</sup>, S. Molenkamp<sup>7</sup>, J.B. Zonneveld<sup>7</sup>, C.J. van Asperen<sup>7</sup>, R.H. Sijmons<sup>8</sup>, D.E. Goldgar<sup>9</sup>, L.J. Rasmussen<sup>5\*</sup>, M.S. Greenblatt<sup>10\*</sup>, Niels de Wind<sup>1\*</sup>, S.V. Tavtigian<sup>2\*</sup>. <sup>1</sup>Dept. of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. <sup>2</sup>Dept. of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, USA. <sup>3</sup>Centre for Epidemiology and Biostatistics, University of Melbourne, Melbourne, Australia. <sup>4</sup>Dept. of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia. <sup>5</sup>Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark.

<sup>6</sup>Dept. of Medicine, Huntsman Cancer Institute, Salt Lake City, USA. <sup>7</sup>Dept. of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. <sup>8</sup>Dept. of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. <sup>9</sup>Dept. of Dermatology, Huntsman Cancer Institute, Salt Lake City, USA. <sup>10</sup>Dept. of Medicine and University, Vermont Cancer Center, Burlington, Vermont, USA. \*Co-corresponding.

15.10 Theepauze expositiehal.

---

**Abstractsessie - Sectie Gastrointestinale Endoscopie****Parkzaal**

---

**Voorzitters :** W.B. Nagengast en J. Honing

- 15.30 Detection of Barrett's esophagus through exhaled breath using a non-invasive screening tool  
Y. Peters<sup>1</sup>, R.W.M. Schrauwen<sup>2</sup>, A.C. Tan<sup>3</sup>, S.K. Bogers<sup>2</sup>, B. de Jong<sup>1</sup>, P.D. Siersema<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Bernhoven Hospital, Uden. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
- 15.40 E-Patient Counseling trial (E-PACO): computer based patient education is non-inferior to nurse counseling prior to colonoscopy, a multicenter randomized controlled trial  
G. Veldhuijzen<sup>1</sup>, M. Klemt-Kropp<sup>2</sup>, J.S. Terhaar sive Droste<sup>3</sup>, B. van Balkom<sup>4</sup>, A.A.J. van Esch<sup>1</sup>, J.P.H. Drenth<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Northwest Clinics, Alkmaar. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Bernhoven Hospital, Uden, The Netherlands.
- 15.50 EndoRotor ablation of Barrett's esophagus; a safety and feasibility study  
A.W. Gotink<sup>1</sup>, Y. Peters<sup>2</sup>, M.J. Bruno<sup>1</sup>, P.D. Siersema<sup>2</sup>, A.D. Koch<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands.
- 16.00 Predictors of adequate sampling in EUS guided TA of solid pancreatic lesions in a large prospective cohort of Dutch community hospitals  
H.M. Schutz<sup>1</sup>, R. Quispel<sup>1</sup>, S.A. Mulder<sup>1</sup>, A.Y. Thijssen<sup>2</sup>, L. Brouwer-Hol<sup>3</sup>, C.E. Fitzpatrick<sup>4</sup>, M.P.G.F. Anten<sup>5</sup>, B.J. Veldt<sup>1</sup>, L.M.J.W. van Driel<sup>6</sup>, M.J. Bruno<sup>6</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Maastad Hospital, Rotterdam. <sup>4</sup>Dept. of Gastroenterology and Hepatology, IJsselland Hospital, Capelle a/d IJssel. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands.
- 16.10 Guidance for setting alternative competence criteria for optical diagnosis of diminutive colorectal polyps which are easier to implement in daily practice - a simulation study  
B.B.S.L. Houwen<sup>1</sup>, M.J. Greuter<sup>2</sup>, J.L.A. Vleugels<sup>1</sup>, Y. Hazewinkel<sup>1</sup>, V.H.M. Coupe<sup>2</sup>, E. Dekker<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC) Amsterdam. <sup>2</sup>Dept. of Epidemiology and Biostatistics, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands.
- 16.20 Single-step treatment with endoscopic resection and cryoballoon ablation is feasible and safe in an esophageal porcine model  
A. Overwater<sup>1</sup>, L.A.A. Brosens<sup>2</sup>, B.L.A.M. Weusten<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital & UMC Utrecht, Utrecht. <sup>2</sup>Dept. of Pathology, UMC Utrecht, Utrecht, The Netherlands.



Woensdag 20 maart 2019

- 16.30 Clinical outcome of endoscopic treatment of symptomatic sterile walled-off necrosis  
*L. Boxhoorn<sup>1</sup>, J.A. Fritschze<sup>1</sup>, P. Fockens<sup>1</sup>, J.E. van Hooft<sup>1</sup>, P.J.F. de Jonge<sup>2</sup>, J.W. Poley<sup>2</sup>, M.J. Bruno<sup>2</sup>, R.P. Voermans<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands.*
- 16.40 Feasibility, safety, tolerability and dose-related efficacy of a novel CryoBalloon Swipe Ablation (CbSAS90) device in dysplastic Barrett's esophagus  
*A. Overwater<sup>1</sup>, S.N. van Munster<sup>2</sup>, G.M. Raicu<sup>3</sup>, C.A. Seldenrijk<sup>3</sup>, W.B. Nagengast<sup>4</sup>, E.J. Schoon<sup>5</sup>, J.J.G.H.M Bergman<sup>2</sup>, B.L.A.M. Weusten<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital & UMC Utrecht, Utrecht. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam. <sup>3</sup>Dept. of Pathology, Pathology DNA, St. Antonius Hospital, Nieuwegein. <sup>4</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands.*
- 16.50 Deep learning algorithm for characterization of Barrett's neoplasia demonstrates high accuracy on NBI-zoom images  
*M.R. Struyvenberg<sup>1</sup>, A.J. de Groof<sup>1</sup>, J. van der Putten<sup>2</sup>, F. van der Sommen<sup>2</sup>, F. Baldaque Silva<sup>3</sup>, R. Bisschops<sup>4</sup>, E.J. Schoon<sup>5</sup>, W.L. Curvers<sup>5</sup>, P.H.N. de With<sup>2</sup>, J.J. Bergman<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Dept. of Electrical Engineering, VCA group, Eindhoven University of Technology, Eindhoven, The Netherlands. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Karolinska University Hospital, Stockholm, Sweden. <sup>4</sup>Dept. of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands.*
- 17.00 Measuring KRAS mutations in pancreatic cyst fluid by droplet digital PCR and Next-Generation Sequencing  
*N.C.M. van Huijgevoort<sup>1</sup>, F. Dijk<sup>2</sup>, J.B.G. Halfwerk<sup>2</sup>, S.J. Lekkerkerker<sup>1</sup>, R.J. Reinten<sup>2</sup>, P. Fockens<sup>1</sup>, M.G. Besselink<sup>3</sup>, O.R. Busch<sup>3</sup>, C.J.M. van Noesel<sup>2</sup>, M.J. van de Vijver<sup>2</sup>, J. Verheij<sup>2</sup>, J.E. van Hooft<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Pathology, <sup>3</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands.*
- 17.10 Treatment of disconnected and disrupted pancreatic duct in necrotizing pancreatitis: a systematic review and meta-analysis  
*S.M. van Dijk<sup>1</sup>, H.C. Timmerhuis<sup>2</sup>, R.C. Verdonk<sup>3</sup>, E. Reijnders<sup>1</sup>, M.J. Bruno<sup>4</sup>, P. Fockens<sup>5</sup>, R.P. Voermans<sup>5</sup>, M.G. Besselink<sup>1</sup>, H.C. van Santvoort<sup>2</sup>. <sup>1</sup>Dept. of Surgery, Amsterdam UMC (loc. AMC), Amsterdam. <sup>2</sup>Dept. of Surgery, St. Antonius Hospital, Nieuwegein. <sup>3</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands.*
- 17.20 Resultaten van Survey van de sectie Endoscopie  
*J. Honing, aios MDL, UMCU, Utrecht*
- 17.30 Plenaire sessie in de Brabantzaal
- 18.45 Congresborrel
- 20.00 Diner in de Beneluxzaal

---

**Meet the expertsessie**

---

**Zaal 80**

**Thema: Pancreascarcinoom**

13.00 – 14.00

*Deze sessie – waarvoor tevoren moet worden ingeschreven - wordt verzorgd door:*

*Prof. dr. M.J. Bruno, MDL-arts, Erasmus MC, Rotterdam  
Dr. M.B.S. Stommel, HPB chirurg, Radboudumc, Nijmegen*

---

**Meet the expertsessie**

---

**Zaal 81**

**Thema: IgG gemedieerde ziekte**

13.00 – 14.00

*Deze sessie – waarvoor tevoren moet worden ingeschreven - wordt verzorgd door:*

*Prof. dr. U.H.W. Beuers, MDL-arts, Amsterdam UMC (loc. AMC), Amsterdam  
Dr. H.R. van Buuren, MDL-arts, Erasmus MC, Rotterdam*

---

**Digitalisering in de zorg**

---

**Zaal 80**

**Voorzitters :** *M.P. Schwartz en J.J. van Dijk-Kuiper*

**Thema: Digitalisering in de zorg**

- 15.30      Introductie minisymposium
- 15.40      MijnIBDCoach  
*Dr. A.E. van der Meulen- de Jong, MDL-arts Leids Universitair Medisch Centrum*
- 16.00      Versnellingsprogramma Informatie-uitwisseling tussen patiënt en professional (VIPP)  
*I. van Es, senior beleidsadviseur NVZ*
- 16.20      Wat kunnen we binnen de MDL met een patiëntenportaal?  
*J.J. van Dijk-Kuiper, MDL-arts Albert Schweitzer ziekenhuis*
- 16.40      Lagerhuisdebat omtrent de digitalisering in de zorg  
*J. Rijpma, Senior Public Affairs Adviseur NVZ*
- 17.00      Plenaire sessie in de Brabantzaal

---

**Symposium – Nederlandse Vereniging voor Gastrointestinale Chirurgie I** **Beneluxhal**

---

**Voorzitters:** *Dr. O. van Ruler en M. Ditzel*

**IBD**

- 09.00 IBD voor Dummies/Chirurgen  
*Prof. dr. G. Dijkstra, MDL-arts, UMCG, Groningen*
- 09.15 IBD-chirurgie in NL: waar zijn we mee bezig?  
*Dr. J.F.M. Lange, chirurg, UMCG, Groningen*
- 09.30 Registreren, who cares? UR-CARE!  
*Dr. J.D.W. van der Bilt, chirurg, Flevoziekenhuis, Almere*
- 09.45 TAMIS in IBD-chirurgie  
*Dr. E.J.R. de Graaf, chirurg, IJsselland ziekenhuis, Capelle a/d IJssel*
- 10.00 Operatieve behandeling Crohnse colitis  
*Prof. dr. L.P.S. Stassen, chirurg, MUMC, Maastricht*
- 10.15 Medicamenteuze onderhoudstherapie versus chirurgie bij Crohn  
*Dr. K.B. Gece, MDL-arts, Amsterdam UMC (loc. AMC), Amsterdam*
- 10.30 Koffiepauze

---

**Symposium – Nederlandse Vereniging voor Gastrointestinale Chirurgie II** **Beneluxhal**

---

**Voorzitters:** *L.P.S. Stassen en H. Cakir*

**Fluorescentie & het colorectaal carcinoom**

- 11.00 Welkom & introductie
- 11.05 Fluorescentie bij endoscopische screening colorectaal carcinoom  
*Dr. W.B. Nagengast, MDL-arts, UMCG, Groningen*
- 11.20 Fluorescentie ter beoordeling perfusie colorectale anastomose  
*Dr. R. Hompes, colorectaal chirurg, Amsterdam UMC (loc. AMC), Amsterdam*
- 11.35 Fluorescentie imaging van de ureter tijdens colorectale chirurgie  
*M. Al Taher, aios/arts-onderzoeker, Zuyderland ziekenhuis/MUMC*
- 11.50 Imaging technieken voor perioperatieve beoordeling colorectale levermetastasen  
*Dr. R.J. Swijnenburg, HPB chirurg, Amsterdam UMC (loc. AMC), Amsterdam*
- 12.05 Tumorspecifieke probes, HIPEC, en andere nieuwe ontwikkelingen  
*Dr. A.L. Vahrmeijer, HPB chirurg, LUMC, Leiden*
- 12.30 Lunchpauze

---

**Symposium – Nederlandse Vereniging voor Gastrointestinale Chirurgie III** **Beneluxhal**

---

**Voorzitter:** Dr. E. van der Harst en A.P.T. van der Ploeg

**Highlights from Lowlands**

- 13.30 Adjuvante hypertherme intraperitoneale chemotherapie (HIPEC) bij patiënten met coloncarcinoom met hoog risico op peritonitis carcinomatosa (COLOPEC trial)  
*C.E.L. Klaver, arts-onderzoeker, Amsterdam UMC (loc. AMC), Amsterdam*
- 13.45 SNAPSHOT study betreffende behandeling obstructief linkszijdig coloncarcinoom  
*F. Amelung, arts-assistent chirurgie, UMCU, Utrecht*
- 14.00 Vroege chirurgische interventie versus huidige stapsgewijze behandeling bij patiënten met chronische pancreatitis (ESCAPE)  
*A.M. Kempeneers, arts-onderzoeker, Amsterdam UMC (loc. AMC), Amsterdam*
- 14.15 Vroege ERC met sfincterotomie versus conservatieve behandeling bij patiënten met voorspeld ernstige biliare pancreatitis (APEC trial)  
*N.J. Schepers, aios MDL, Albert Schweitzer ziekenhuis, Dordrecht*
- 14.30 Chirurgie versus conservatieve behandeling van recidiverende diverticulitis en persisterende klachten na diverticulitis: 5 jaar uitkomsten van de DIRECT-Trial  
*H. Bolkenstein, arts-onderzoeker, Meander Medisch Centrum, Amersfoort*
- 14.45 Lange termijn oncologische en functionele uitkomsten van chemoradiatie gevolgd door orgaansparende transanale endoscopische microchirurgie voor het distale rectumcarcinoom: de CARTS Studie.  
*Dr. R. Stijns, arts-onderzoeker, Radboudumc, Nijmegen*
- 15.00 Laparoscopische cholecystectomie versus percutane catheter drainage bij hoog-risico patiënten met acute cholecystitis (CHOCOLATE trial)  
*Dr. C.S. Loozen, arts-onderzoeker, St. Antonius ziekenhuis, Nieuwegein*
- 15.30 Einde programma

---

**Abstractsessie - Sectie Gastrointestinale Oncologie**

---

**Auditorium**

**Voorzitters :** L. van Vlerken en n.t.b.

- 09.30 Is decompressing stoma a better alternative than stent as bridge to surgery for left-sided obstructive colon cancer? A nationwide, propensity score matched analysis  
*J.V. Veld<sup>1</sup>, F.J. Amelung<sup>2</sup>, W.A.A. Borstlap<sup>1</sup>, E.E. van Halsema<sup>3</sup>, E.C.J. Consten<sup>2</sup>, P.D. Siersema<sup>4</sup>, F. ten Borg<sup>5</sup>, E.S. van der Zaag<sup>6</sup>, P. Fockens<sup>3</sup>, W.A. Bemelman<sup>1</sup>, J.E. van Hooff<sup>3</sup>, P.J. Tanis<sup>1</sup>.  
<sup>1</sup>Dept. of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>2</sup>Dept. of Surgery, Meander MC, Amersfoort, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, <sup>5</sup>Dept. of Surgery, Deventer Hospital, Deventer, <sup>6</sup>Dept. of Surgery, Gelre Hospital, Apeldoorn, The Netherlands.*

Donderdag 21 maart 2019

- 9.40 Changes in management of left-sided obstructive colon cancer: national practice and guideline implementation  
J.V. Veld<sup>1</sup>, F.J. Amelung<sup>2</sup>, W.A.A. Borstlap<sup>1</sup>, E.E. van Halsema<sup>3</sup>, E.C.J. Consten<sup>2</sup>, P.D. Siersema<sup>4</sup>, F. ten Borg<sup>5</sup>, E.S. van der Zaag<sup>6</sup>, P. Fockens<sup>3</sup>, W.A. Bemelman<sup>1</sup>, J.E. van Hooft<sup>3</sup>, P.J. Tanis<sup>1</sup>.  
<sup>1</sup>Dept. of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>2</sup>Dept. of Surgery, Meander MC, Amersfoort, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, <sup>5</sup>Dept. of Surgery, Deventer Hospital, Deventer, <sup>6</sup>Dept. of Surgery, Gelre Hospital, Apeldoorn, The Netherlands.
- 9.50 Early detection of colorectal cancer and advanced adenomas based on faecal volatile organic compounds  
S. Bosch<sup>1</sup>, R. Bot<sup>1</sup>, A. Wicaksono<sup>2</sup>, J. Kuijvenhoven<sup>3</sup>, R. van der Hulst<sup>3</sup>, P. Stokkers<sup>4</sup>, J.A. Covington<sup>2</sup>, T.G.J. de Meij<sup>5</sup>, N.K.H. de Boer<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands. <sup>2</sup>School of Engineering, University of Warwick, Coventry, United Kingdom. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Spaarne Gasthuis, Hoofddorp/Haarlem, The Netherlands. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis West, Amsterdam, The Netherlands. <sup>5</sup>Dept. of Pediatrics, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands.
- 10.00 Interval cancers after a negative faecal immunochemical test in the first screening round in the Netherlands for two cut-off levels  
E. Toes-Zoutendijk<sup>1</sup>, A.I. Kooyker<sup>1</sup>, E. Dekker<sup>2</sup>, M.C.W. Spaander<sup>3</sup>, A.W.J. Opstal-van Winden<sup>1</sup>, C. Ramakers<sup>4</sup>, M. Buskermolen<sup>1</sup>, A.J. van Vuuren<sup>3</sup>, E.J. Kuipers<sup>3</sup>, F.J. Kemenade<sup>5</sup>, M.F. Velthuysen<sup>5</sup>, M.G.J. Thomeer<sup>6</sup>, H. van Veldhuizen<sup>7</sup>, M. van Ballegooijen<sup>1</sup>, I. Nagtegaal<sup>8</sup>, H.J. Koning<sup>1</sup>, M. van Leerdam<sup>9</sup>, I. Lansdorp-Vogelaar<sup>1</sup>. <sup>1</sup>Dept. of Public Health, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>4</sup>Dept. of Clinical Laboratory, Erasmus MC, Rotterdam, <sup>5</sup>Dept. of Pathology, Erasmus MC, Rotterdam, <sup>6</sup>Dept. of Radiology, Erasmus MC, Rotterdam, <sup>7</sup>IQ Healthcare, Erasmus MC, Rotterdam, <sup>8</sup>Dept. of Pathology, Radboudumc, Nijmegen, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
- 10.10 Post-colonoscopy mortality in a FIT-based colorectal cancer screening program  
A.I. Kooyker<sup>1</sup>, E. Toes-Zoutendijk<sup>2</sup>, A.W.J. Opstal-van Winden<sup>2</sup>, M.C.W. Spaander<sup>3</sup>, E. Dekker<sup>4</sup>, M. Buskermolen<sup>2</sup>, A.J. van Vuuren<sup>3</sup>, E.J. Kuipers<sup>3</sup>, F.J. van Kemenade<sup>5</sup>, H. van Veldhuizen<sup>2</sup>, M.G.J. Thomeer<sup>6</sup>, I. Nagtegaal<sup>7</sup>, C. Ramakers<sup>8</sup>, M. van Ballegooijen<sup>2</sup>, H. Koning<sup>2</sup>, I. Lansdorp-Vogelaar<sup>2</sup>, M.E. van Leerdam<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology, Netherlands Cancer Institute, Amsterdam, <sup>2</sup>Dept. of Public Health, Erasmus MC, Rotterdam, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam, <sup>5</sup>Dept. of Pathology, Erasmus MC, Rotterdam, <sup>6</sup>Dept. of Radiology, Erasmus MC, Rotterdam, <sup>7</sup>Dept. of Pathology, Radboudumc, Nijmegen, <sup>8</sup>Dept. of Cell and Chemical Biology, Erasmus MC, Rotterdam, The Netherlands.
- 10.20 Joint surgical and gastroenterological assessment to decide on the optimal treatment of early colorectal neoplasia.  
K.M. Gijbers<sup>1</sup>, A.K. Talsma<sup>2</sup>, R.J.I. Bosker<sup>2</sup>, F. ten Borg<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology, <sup>2</sup>Dept. of Surgery, Deventer Hospital, Deventer, The Netherlands.
- 10.30 Pauze

---

**Symposium - Sectie Gastrointestinale Oncologie****Auditorium**

---

**Voorzitters :** L. Brouwer- Hol en M. Bigirwamungu-Bargeman

**Shared decision making**

- 11.00 Casuïstiek  
Aios MDL
- 11.10 “De kunst van het samen beslissen”  
Dr. A. Pieterse, cognitief psycholoog, UHD medische besliskunde, LUMC
- 11.35 “Samen beslissen in de dagelijkse praktijk”  
Dr. M. van der Kolk, GE-chirurg, Radboudumc, Nijmegen
- 12.05 “To care or to cure? Behandeling van oudere patiënten met kanker”  
Dr. Frederiek van den Bos, internist-ouderengeneeskunde, UMC, Utrecht
- 12.30 Lunchpauze

---

**Abstractsessie - Sectie Experimentele Gastroenterologie****Baroniezaal**

---

**Voorzitters :** D.M.A.E. Jonkers en L.J.A.C. Hawinkels

- 09.00 Discovery and selection of HBV-derived T cell targets for global immunotherapy based on HLA binding, conservation and viral indispensability  
M.T.A. de Beijer<sup>1</sup>, D.T.S.L. Jansen<sup>1</sup>, Y. Dou<sup>1</sup>, W.J.E. van Esch<sup>2</sup>, J.Y. Mok<sup>2</sup>, M.J.P. Maas<sup>2</sup>, G. Brasser<sup>2</sup>, R.A. de Man<sup>1</sup>, A.M. Woltman<sup>1</sup>, S.I. Buschow<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam. <sup>2</sup>Dept. of Research & Development, Sanquin, Amsterdam, The Netherlands.
- 09.12 Mass spectrometry analysis of HLA class I peptides presented on human hepatocytes and hepatocellular carcinoma to guide antigen-based immunotherapy  
M.T.A. de Beijer<sup>1</sup>, K. Bezstarosti<sup>2</sup>, R. Bouzid<sup>1</sup>, P.J. Biesta<sup>1</sup>, R.A. de Man<sup>1</sup>, A.M. Woltman<sup>1</sup>, J.A. Demmers<sup>2</sup>, S.I. Buschow<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Proteomics Center, Erasmus MC, Rotterdam, The Netherlands.
- 09.24 Combined TRC105/PDI therapy synergistically inhibits tumor growth by targeting immune suppressing cells and activation cytotoxic responses  
M.J.A. Schoonderwoerd<sup>1</sup>, R. Angela<sup>1</sup>, M. Koops<sup>1</sup>, C.P. Theuer<sup>2</sup>, J.C.H. Hardwick<sup>1</sup>, M.F. Fransen<sup>3</sup>, L.J.A.C. Hawinkels<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden, The Netherlands. <sup>2</sup>Dept. of Scientific Research, TRACON Pharmaceuticals, San Diego, United States of America. <sup>3</sup>Dept. of Immunohematology and Blood Transfusion, Leiden UMC, Leiden, The Netherlands.
- 09.36 VCAM/Endoglin positive subpopulations of Mesenchymal Stromal (stem) Cells reverse fibrogenesis in experimental liver fibrosis  
D. van der Helm, J.J. Habibe, M.C. Barnhoorn, E.S.M. de Jonge-Muller, M.J. Coenraad, B. van Hoek, H.W. Verspaget. Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden, The Netherlands.

- 09.48      Pasteurized whey protein improves maturation of the immature intestine of preterm and near-term piglets  
*M. Navis<sup>1</sup>, V. Muncan<sup>1</sup>, P.T. Sangild<sup>2</sup>, L. Møller Willumsen<sup>2</sup>, P. Koelink<sup>1</sup>, M.E. Wildenberg<sup>1</sup>, E. Abrahamse<sup>3,4</sup>, T. Thymann<sup>2</sup>, R.M. van Elburg<sup>3,5</sup>, I.B. Renes<sup>3,5</sup>.* <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Comparative Pediatrics & Nutrition, University of Copenhagen, Copenhagen, Denmark. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Danone Nutricia Research, Utrecht, The Netherlands. <sup>4</sup>Laboratory of Food Chemistry, Wageningen University, Wageningen, The Netherlands. <sup>5</sup>Dept. of Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, The Netherlands.
- 10.00      Autophagy regulates Rac1GTP and RhoAGTP activity in dendritic cells and epithelial cell lines  
*M.M.C. Prins, F.P. Giugliano, P.J. Koelink, G.R. van der Brink, M.E. Wildenberg.* Dept. of Gastroenterology and Hepatology, Tytgat Institute for Intestinal and Liver Research, Amsterdam, The Netherlands.
- 10.12      Whole-exome sequencing in early-onset primary sclerosing cholangitis: first results of the WHELP-study  
*S.M. Haisma<sup>1</sup>, R.K. Weersma<sup>2</sup>, M.E. Joosse<sup>3</sup>, B.A.E. de Koning<sup>3</sup>, T. de Meij<sup>4</sup>, B.G.P. Koot<sup>5</sup>, V.W. Wolters<sup>6</sup>, O. Norbruis<sup>7</sup>, M.J. Daly<sup>8</sup>, C. Stevens<sup>8</sup>, R.J. Xavier<sup>8</sup>, M.A. Rivas<sup>9</sup>, M.C. Visschedijk<sup>2</sup>, H.J. Verkade<sup>1</sup>, R. Barbieri<sup>2</sup>, B.H. Jansen<sup>2</sup>, E.A.M. Festen<sup>2</sup>, P.F. van Rheenen<sup>1</sup>, C.C. van Diemen<sup>10</sup>.* <sup>1</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, UMC Groningen, Groningen, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen, The Netherlands. <sup>3</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Erasmus MC, Rotterdam, The Netherlands. <sup>4</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands. <sup>5</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands. <sup>6</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, UMC Utrecht, Utrecht, The Netherlands. <sup>7</sup>Dept. of Pediatrics, Isala, Zwolle, The Netherlands. <sup>8</sup>Dept. of Biomedical Data Sciences, Broad Institute of Harvard and Massachusetts Institute of Technology, Boston, United States of America. <sup>9</sup>Dept. of Biomedical Data Sciences, Stanford University, Stanford, United States of America. <sup>10</sup>Dept. of Clinical Genetics, UMC Groningen, Groningen, The Netherlands.
- 10.30      Koffiepauze in de expositiehal

---

**Abstractsessie - Sectie Experimentele Gastroenterologie**

**Baroniezaal**

**Voorzitters :** D.M.A.E. Jonkers en N. Festen

- 11.00      Loss of intestinal Indian Hedgehog enhances Apc-driven tumorigenesis  
*B.F. Westendorp, O.N. Karpus, M. van Roest, S. Meisner, N.V.J.A. Büller, M.E. Wildenberg, V. Muncan, G.R. van den Brink.* Dept. of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands.
- 11.12      Loss of the Bone Morphogenetic Protein signalling in myofibroblasts initiates polyp formation in the mouse intestine  
*S. Ouahoud<sup>1</sup>, L.R.A. van der Burg<sup>1</sup>, P.W. Voorneveld<sup>1</sup>, C. Steenkamp<sup>1</sup>, J.A.D.E. Erinkveld<sup>1</sup>, E.S.M. de Jonge-Muller<sup>1</sup>, G.J. Offerhaus<sup>3</sup>, L.J.A.C. Hawinkels<sup>1</sup>, J.C.H. Hardwick<sup>1</sup>.* <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden, <sup>2</sup>Dept. of Pathology, UMC Utrecht, Utrecht, The Netherlands.

- 11.24 Inhibition of BMP2 and BMP4 eradicates Barrett's esophagus and enhances the regeneration of squamous epithelium  
K.K. Krishnadath<sup>1,2</sup>, A. Correia<sup>1</sup>, D. Straub<sup>1</sup>, S.J.M. Hoefnagel<sup>1</sup>, S. Calpe<sup>1</sup>, M. Read<sup>3</sup>, W. Philips<sup>3</sup>.  
<sup>1</sup>Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>3</sup>Dept. of Experimental Surgery, Peter MacCallum Oncology Center, Melbourne, Australia.
- 11.36 A chemoradiotherapy treatment response mRNA signature as predictor for esophageal adenocarcinoma treated according to the CROSS regimen  
K.K. Krishnadath<sup>1,2,8</sup>, S.J.M. Hoefnagel<sup>1,2</sup>, J. Koster<sup>3</sup>, W.J. Koemans<sup>4</sup>, J.M. van Dieren<sup>5</sup>, J.W. van Sandick<sup>4</sup>, L.L. Kodach<sup>6</sup>, S. Calpe<sup>1</sup>, S.L. Meijer<sup>7,8</sup>, C.M. del Sancho-Serra<sup>1</sup>, H.N. Khan<sup>1</sup>, H.W.M. van Laarhoven<sup>8</sup>, M.I. van Berge Henegouwen<sup>8</sup>, S.S. Gisbertz<sup>8</sup>, M.C.C.M. Hulshof<sup>8</sup>. <sup>1</sup>Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>3</sup>Dept. of Oncogenomics, Amsterdam UMC, Amsterdam, <sup>4</sup>Dept. of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, <sup>5</sup>Dept. of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, <sup>6</sup>Dept. of Pathology, The Netherlands Cancer Institute, Amsterdam, <sup>7</sup>Dept. of Pathology, Amsterdam UMC, Amsterdam, <sup>8</sup>Esophageal Cancer Workgroup, Amsterdam UMC, Amsterdam, The Netherlands.
- 11.48 Genetic variants of innate immunity receptors are associated with mortality but not with bacterial infections in liver cirrhosis  
J.J. Schaapman<sup>1</sup>, A. Amoros<sup>2</sup>, J.J. van der Reijden<sup>3</sup>, W. Laleman<sup>4</sup>, S. Zeuzem<sup>5</sup>, R. Bañares<sup>6</sup>, R. Jalan<sup>7</sup>, V. Arroyo<sup>2</sup>, H.W. Verspaget<sup>3</sup>, M.J. Coenraad<sup>3</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden, The Netherlands. <sup>2</sup>Dept. of Hepatology, European Foundation for the study of chronic liver failure, Barcelona, Spain. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden, The Netherlands. <sup>4</sup>Dept. of Gastroenterology and Hepatology, UZ Leuven, Leuven, Belgium. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Universitätsklinikum Frankfurt, Frankfurt, Germany. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Gregorio Marañón Hospital, Madrid, Spain. <sup>7</sup>Dept. of Gastroenterology and Hepatology, University College London Hospital, London, United Kingdom.
- 11.51 The effects of citrus flavonoids on intestinal permeability and inflammation using an in vitro co-culture model  
Y. Stevens<sup>1,2</sup>, A.A.M. Masclee<sup>1</sup>, T. de Bie<sup>2</sup>, L. van de Ven<sup>2</sup>, D. Jonkers<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, <sup>2</sup>Dept. of Scientific Research, BioActor B.V., Maastricht, The Netherlands.
- 11.54 HNF4A is essential for intestinal epithelial regeneration upon radiation-induced injury  
S.P. Montenegro-Miranda<sup>1</sup>, J.H.M. van der Meer<sup>1</sup>, C. Jones<sup>2</sup>, S. Meisner<sup>1</sup>, J.L.M. Vermeulen<sup>1</sup>, F. Boudreau<sup>2</sup>, A. Ribeiro<sup>3</sup>, G.R. van den Brink<sup>1</sup>, V. Muncan<sup>1</sup>. <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. <sup>2</sup>Département Pavillon de recherche appliquée sur le cancer, Sherbrooke, Canada, <sup>3</sup>Centre de Recherche des Cordeliers, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France.
- 11.57 Luminal preservation of the human small bowel graft reduces mucosal damage during cold storage  
G. Trentadue<sup>1</sup>, A.M. de Jong<sup>1</sup>, J. van Praagh<sup>2</sup>, M. Clarysse<sup>3</sup>, E. Canovai<sup>4</sup>, L. Ceulemans<sup>5</sup>, J. Pirenne<sup>5</sup>, J.W. Haveman<sup>6</sup>, K.N. Faber<sup>1</sup>, G. Dijkstra<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen, The Netherlands. <sup>2</sup>Dept. of Clinical Pharmacy, UMC Groningen, Groningen, The Netherlands. <sup>3</sup>Dept. of Gastrointestinal Surgery, University Hospitals Leuven, Leuven, Belgium. <sup>4</sup>Dept. of Surgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands. <sup>5</sup>Dept. of Surgery, University Hospitals Leuven, Leuven, Belgium. <sup>6</sup>Dept. of Surgery, UMC Groningen, Groningen, The Netherlands.



Donderdag 21 maart 2019

- 12.00 Battle (3x 5 min presentaties)
- 12.15 Abstract en battle prijs
- 12.30 Lunchpauze

---

**Abstractsessie - Nederlandse Vereniging voor Gastroenterologie****Parkzaal**

---

**Voorzitters:** W.H. de Vos tot Nederveen Cappel en J.M. Conchillo

- 09.00 A history of cholecystectomy is associated with higher rates of metabolic syndrome and nonalcoholic fatty liver disease: a population based study  
C.S.S. Latenstein<sup>1</sup>, L.J.M. Alferink<sup>2</sup>, S. Darwish Murad<sup>2</sup>, J.P.H. Drenth<sup>3</sup>, C.J.H.M. van Laarhoven<sup>1</sup>, P.R. de Reuver<sup>4</sup>. <sup>1</sup>Dept. of Surgery, Radboudumc, Nijmegen, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, <sup>4</sup>Dept. of Gastrointestinal Surgery, Radboudumc, Nijmegen, The Netherlands.
- 09.10 Ethnicity and response to primary standard three-dose hepatitis B vaccination in employees in The Netherlands. 1983 through 2017  
Ö.M. Koc<sup>1</sup>, C. Menart<sup>2</sup>, J. Theodore<sup>2</sup>, C. Kremer<sup>3</sup>, N. Hens<sup>3</sup>, G.H. Koek<sup>2</sup>, A.M.L. Oude Lashof<sup>1</sup>. <sup>1</sup>Dept. of Medical Microbiology, Maastricht UMC, Maastricht, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, The Netherlands. <sup>3</sup>Dept. of Clinical Epidemiology, Hasselt University, Hasselt, Belgium.
- 09.20 Serum lipidomics profiling as a diagnostic tool for NAFLD in children: a matched case-control pilot study  
L.G. Draijer<sup>1</sup>, D. Torenstra<sup>1</sup>, A.E. Bohte<sup>2</sup>, F.M. Vaz<sup>3</sup>, M. van Weeghel<sup>3</sup>, M.A. Benninga<sup>1</sup>, B.G.P. Koot<sup>1</sup>. <sup>1</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, <sup>2</sup>Dept. of Radiology and Nuclear Medicine, <sup>3</sup>Dept. of Gastroenterology and Metabolism, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands.
- 09.30 Risk factors for symptomatic gallstone disease after Roux-en-Y gastric bypass  
S. Haal<sup>1</sup>, D. Rondagh<sup>2</sup>, P. Fockens<sup>1</sup>, B.A. Hutten<sup>3</sup>, Y.I.Z. Acherman<sup>4</sup>, R.P. Voermans<sup>1</sup>, V.E.A. Gerdes<sup>2</sup>, R. Huijgen<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC (loc. AMC), Amsterdam, <sup>2</sup>Dept. of Internal Medicine, MC Slotervaart, Amsterdam, <sup>3</sup>Dept. of Epidemiology, Amsterdam UMC (loc. AMC), Amsterdam, <sup>4</sup>Dept. of Surgery, MC Slotervaart, Amsterdam, The Netherlands.
- 09.40 A multicentre randomized non-inferiority trial comparing usual care to restrictive strategy for use of cholecystectomy in patients with gallstones and abdominal pain (SECURE trial)  
A.H. van Dijk<sup>1</sup>, S.Z. Wennmacker<sup>2</sup>, P.R. de Reuver<sup>2</sup>, C.S.S. Latenstein<sup>2</sup>, O. Buyne<sup>3</sup>, S.C. Donkervoort<sup>4</sup>, Q.A.J. Eijssbouts<sup>5</sup>, J. Heisterkamp<sup>6</sup>, K. in t Hof<sup>7</sup>, J. Janssen<sup>8</sup>, V.B. Nieuwenhuis<sup>9</sup>, H.M. Schaap<sup>10</sup>, P. Steenvoorde<sup>11</sup>, H.B.A.C. Stockmann<sup>5</sup>, D. Boerma<sup>12</sup>, G.P. Westert<sup>13</sup>, J.P.H. Drenth<sup>14</sup>, M.G.W. Dijkgraaf<sup>15</sup>, M.A. Boermeester<sup>1</sup>, C.J.H.M. van Laarhoven<sup>2</sup>. <sup>1</sup>Dept. of Surgery, Amsterdam UMC (loc. AMC), Amsterdam, <sup>2</sup>Dept. of Surgery, Radboudumc, Nijmegen, <sup>3</sup>Dept. of Surgery, Maashospital Pantein, Boxmeer, <sup>4</sup>Dept. of Surgery, Onze Lieve Vrouwe Gasthuis East, Amsterdam, <sup>5</sup>Dept. of Surgery, Spaarne Gasthuis, Hoofddorp, <sup>6</sup>Dept. of Surgery, Elisabeth-Tweesteden Hospital, Tilburg, <sup>7</sup>Dept. of Surgery, Flevohospital, Almere, <sup>8</sup>Dept. of Surgery, Admiraal de Ruyter Hospital, Goes, <sup>9</sup>Dept. of Surgery, Isala, Zwolle, <sup>10</sup>Dept. of Surgery, Treant Zorggroep, Emmen, <sup>11</sup>Dept. of Surgery, Medisch Spectrum Twente, Enschede, <sup>12</sup>Dept. of Surgery, Antonius Hospital, Nieuwegein, <sup>13</sup>Dept. of Research & Development, Radboudumc, Nijmegen, <sup>14</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, <sup>15</sup>Dept. of Clinical Epidemiology, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands.

Donderdag 21 maart 2019

- 09.50 Per-oral endoscopic pyloromyotomy for severe refractory gastroparesis: a feasibility and efficacy study in the Netherlands  
*J.M. Conchillo<sup>1</sup>, J.W. Straathof<sup>1</sup>, E.L. Venema<sup>1</sup>, N.D. Bouvy<sup>2</sup>, A.A.M. Masclee<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Surgery, Maastricht UMC, Maastricht, The Netherlands.*
- 10.00 Long-term follow-up of gut-directed hypnotherapy self-exercises at home using CD versus individual therapy by qualified therapists in children with irritable bowel syndrome or functional abdominal pain (syndrome)  
*R. Rexwinkel<sup>1</sup>, A.M. Vlieger<sup>2</sup>, J.F.M. Bovendeert<sup>1</sup>, J.M.T.M. Rutten<sup>1</sup>, C. Frankenhuis<sup>1</sup>, M.A. Benninga<sup>1</sup>. <sup>1</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Emma Children's Hospital, Amsterdam, <sup>2</sup>Dept. of Pediatrics, St. Antonius Hospital, Nieuwegein, The Netherlands.*
- 10.10 Reduction in IBS symptom severity does not result in improved quality of life in patients with irritable bowel syndrome  
*Z.Z.R.M. Weerts, L. Vork, Z. Mujagic, D. Keszthelyi, M. Hesselink, D.M.A.E. Jonkers, A.A.M. Masclee. Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, The Netherlands.*
- 10.20 Koffiepauze

---

**Abstractsessie - Sectie Neurogastroenterologie en Motiliteit**

**Parkzaal**

---

**Voorzitters :** *J.M. Conchillo en F.B. van Hoeij*

- 11.00 Day-to-day variability in fecal microbiota and its association with stool consistency: do we need repeated sample collection on the short-term?  
*L. Vork<sup>1</sup>, J. Penders<sup>2</sup>, S. van Kuijk<sup>3</sup>, J. Jalanka<sup>4</sup>, M. Rajilic-Stojanovic<sup>5</sup>, C. Bojic<sup>5</sup>, C. Manichanh<sup>6</sup>, M. Pozuelo<sup>6</sup>, A.A.M. Masclee<sup>1</sup>, D. Jonkers<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, The Netherlands. <sup>2</sup>Dept. of Medical Microbiology, Maastricht UMC, Maastricht, The Netherlands. <sup>3</sup>Dept. of Clinical Epidemiology and Medical Technology Assessment, Maastricht UMC, Maastricht, The Netherlands. <sup>4</sup>Dept. of Medical Microbiology, University of Helsinki, Helsinki, Finland, <sup>5</sup>Dept. of Chemical and Biomolecular Engineering, University of Belgrade, Belgrade, Serbia, <sup>6</sup>Dept. of Digestive Diseases, University Hospital Vall d'Hebron, Barcelona, Spain.*
- 11.10 Physiotherapy for children with functional constipation: a pragmatic randomized controlled trial in primary care  
*J.J.G.T. van Summeren<sup>1</sup>, G.A. Holtman<sup>1</sup>, B.J. Kollen<sup>1</sup>, Y. Lisman-van Leeuwen<sup>1</sup>, A.H.C. van Ulsen-Rust<sup>2</sup>, M.M. Tabbers<sup>3</sup>, J.H. Dekker<sup>1</sup>, M.Y. Berger<sup>1</sup>. <sup>1</sup>Dept. of General Practice and Elderly Care Medicine, UMC Groningen, Groningen, <sup>2</sup>Dept. of Physiotherapy, Pelvicum children's pelvic physiotherapy, Groningen, <sup>3</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Emma Children's Hospital, Amsterdam UMC (loc. AMC), Amsterdam, The Netherlands.*
- 11.20 Opioid usage is significantly associated with rectal hyposensitivity and functional evacuation disorders in patients with chronic constipation  
*P.F. Vollebregt, S.M. Scott, J. Miller, C.H. Knowles. Centre for Trauma and Surgery and GI Physiology Unit, Queen Mary University of London, London, United Kingdom.*
- 11.30 A prospective evaluation of gastrointestinal symptoms and dysmotility in subjects with and without Hypermobility Spectrum Disorders  
*L. Vork<sup>1</sup>, A.A.M. Masclee<sup>1</sup>, A. Beckers<sup>1</sup>, J. Conchillo<sup>1</sup>, J. Kruimel<sup>1</sup>, Q. Aziz<sup>2</sup>, D. Keszthelyi<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Queen Mary University of London, London, United Kingdom.*

Donderdag 21 maart 2019

- 11.40 Diagnostic value of inflammatory parameters in the work-up of functional abdominal pain  
*J. Zeevenhooven<sup>1</sup>, R. Rexwinkel<sup>1</sup>, E. Tromp<sup>2</sup>, M.A. Benninga<sup>1</sup>, A.M. Vlieger<sup>2</sup>. <sup>1</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>2</sup>Dept. of Pediatrics, St. Antonius Hospital, Nieuwegein, The Netherlands.*
- 11.50 The socioeconomic burden of IBS in a Dutch population  
*Z.Z.R.M. Weerts<sup>1</sup>, D. Keszthelyi<sup>1</sup>, J. Willems<sup>1</sup>, D.J.P.A. Janssen<sup>1</sup>, B. Essers<sup>2</sup>, D.M.A.E. Jonkers<sup>1</sup>, A.A.M. Masclee<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Clinical Epidemiology and Medical Technology Assessment, Maastricht UMC, Maastricht, The Netherlands.*
- 12.00 Prevalence of child abuse in children with functional constipation  
*M.H. Vriesman<sup>1</sup>, T.F. Vrolijk-Bosschaart<sup>2</sup>, S.N. Brilleslijper-Kater<sup>2</sup>, A.H. Teeuw<sup>2</sup>, R.J.L. Lindauer<sup>3</sup>, M.A. Benninga<sup>1</sup>. <sup>1</sup>Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>2</sup>Dept. of Social Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>3</sup>Dept. of Child and Adolescent Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.*
- 12.10 A smartphone application for symptom assessment and data collection in medical trials: example from an IBS drug intervention trial  
*Z.Z.R.M. Weerts, A.B.A. Quanjel, L. Vork, D.M.A.E. Jonkers, A.A.M. Masclee, D. Keszthelyi. Dept. of Gastroenterology and Hepatology, Maastricht UMC, Maastricht, The Netherlands.*
- 12.20 Coexistence of fecal incontinence and constipation in adults is an underappreciated clinical problem  
*P.F. Vollebregt, U. Grossi, R.P. McCaughan, C.H. Knowles, S.M. Scott. Centre for Trauma and Surgery and GI Physiology Unit, Queen Mary University of London, London, United Kingdom.*
- 12.30 Lunchpauze

---

**Abstractsessie - Nederlandse Vereniging voor Gastrointestinale Chirurgie I** **Zaal 80**

---

**Voorzitters :** M. Coolen en J.A.M.G. Tol

- 09.30 Proposed method for adequate surgical gallbladder examination  
*B.J.G.A. Corten<sup>1</sup>, W.K.G. Leclercq<sup>1</sup>, P.H. van Zwam<sup>2</sup>, R.M.H. Roumen<sup>1</sup>, G.D. Slooter<sup>1</sup>. <sup>1</sup>Dept. of Surgery, Máxima Medical Center, Veldhoven, <sup>2</sup>Dept. of Pathology, Laboratory for Pathology and Medical Microbiology (PAMM), Veldhoven, The Netherlands.*
- 09.40 Selective histological examination after cholecystectomy; an analysis of current daily practice in the Netherlands  
*B.J.G.A. Corten, W.K.G. Leclercq, R.M.H. Roumen, G.D. Slooter. Dept. of Surgery, Máxima Medical Center, Veldhoven, The Netherlands.*
- 09.50 Nationwide outcome including long-term quality of life after total pancreatectomy (PANORAMA)  
*A.E.J. Latenstein<sup>1</sup>, L. Scholten<sup>1</sup>, J.E. van Hooft<sup>2</sup>, B.A. Bonsing<sup>3</sup>, K. Bosscha<sup>4</sup>, P.P.L.O. Coene<sup>5</sup>, R.M. van Dam<sup>6</sup>, S. van Dieren<sup>1</sup>, C.H.J. van Eijck<sup>7</sup>, J. Erdmann<sup>8</sup>, M.F. Gerhards<sup>8</sup>, H. van Goor<sup>8</sup>, E. van der Harst<sup>8</sup>, I.H. de Hingh<sup>8</sup>, G. Kazemier<sup>8</sup>, J.M. Klaase<sup>8</sup>, S. Mieog<sup>8</sup>, I.Q. Molenaar<sup>8</sup>, G. Patijn<sup>8</sup>, H. van Santvoort<sup>8</sup>, J.J. Scheepers<sup>8</sup>, G.P. van der Schelling<sup>8</sup>, F.J. Snoek<sup>8</sup>, B.K. Pranger<sup>8</sup>, O.R.C. Busch<sup>1</sup>, J.H. DeVries<sup>8</sup>, M.G. Besselink<sup>1</sup>. <sup>1</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of*

Donderdag 21 maart 2019

Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>3</sup>Dept. of Surgery, Leiden UMC, Leiden, <sup>4</sup>Dept. of Surgery, Jeroen Bosch Hospital, Den Bosch, <sup>5</sup>Dept. of Surgery, Maastricht Hospital, Rotterdam, <sup>6</sup>Dept. of Surgery, Maastricht UMC, Maastricht, <sup>7</sup>Dept. of Surgery, Erasmus MC, Rotterdam, <sup>8</sup>Dept. of Surgery, Amsterdam UMC (loc. VUmc), Amsterdam, The Netherlands.

- 10.00 Textbook outcome as a novel quality measure in pancreatic surgery: a nationwide analysis  
S. van Roessel<sup>1</sup>, T.M. Mackay<sup>2</sup>, S. van Dieren<sup>2</sup>, G.P. van der Schelling<sup>2</sup>, V.B. Nieuwenhuijs<sup>2</sup>, K. Bosscha<sup>2</sup>, E. van der Harst<sup>2</sup>, R.M. van Dam<sup>2</sup>, M.S.L. Liem<sup>2</sup>, S. Festen<sup>2</sup>, M.W.J. Stommel<sup>2</sup>, D. Roos<sup>2</sup>, F. Wit<sup>2</sup>, I.Q. Molenaar<sup>2</sup>, V.E. de Meijer<sup>2</sup>, I.H.J.T. de Hingh<sup>2</sup>, H.C. van Santvoort<sup>2</sup>, B.A. Bonsing<sup>2</sup>, O.R.C. Busch<sup>2</sup>, B. Groot Koerkamp<sup>2</sup>, M.G.H. Besselink<sup>2</sup>. <sup>1</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Surgery, Reinier de Graaf Gasthuis, Delft, The Netherlands.
- 10.10 Comparing the revised European, AGA and IAP guidelines on pancreatic cystic neoplasms: accuracy in identifying advanced neoplasia in IPMN  
N.C.M. van Huijgevoort<sup>1</sup>, S. ten Bokkel-Huinink<sup>1</sup>, S.J. Lekkerkerker<sup>1</sup>, I. Somers<sup>2</sup>, M. Del Chiaro<sup>3</sup>, P. Fockens<sup>1</sup>, M.G. Besselink<sup>4</sup>, J.E. van Hooft<sup>1</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Dept. of Radiology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>3</sup>Dept. of Surgery, University of Colorado Anschutz Medical Campus, Aurora, United States of America. <sup>4</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
- 10.20 Risk factors for the development of vascular complications after liver transplantation  
Y. Li<sup>1</sup>, L.M. Nieuwenhuis<sup>2</sup>, M.J.M. Werner<sup>2</sup>, R.J. Porte<sup>2</sup>, O.B. van Leeuwen<sup>2</sup>, H. Blokzijl<sup>1</sup>, E.A.M. Festen<sup>1</sup>, V.E. de Meijer<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, <sup>2</sup>Dept. of Surgery, UMC Groningen, Groningen, The Netherlands.
- 10.30 Koffiepauze

---

**Abstractsessie - Nederlandse Vereniging voor Gastrointestinale Chirurgie II** **Zaal 80**

---

**Voorzitters :** R.J.J. Verhage en G. Vijgen

- 11.00 Palliative gastrectomy for advanced gastric cancer does not result in additional morbidity compared to curative gastrectomy  
E.C. Gertsen<sup>1</sup>, H.J.F. Brenkman<sup>2</sup>, L. Goense<sup>3</sup>, N. Haj Mohammad<sup>4</sup>, B.L.A.M. Weusten<sup>5</sup>, R. van Hillegersberg<sup>1</sup>, J.P. Ruurda<sup>1</sup>. <sup>1</sup>Dept. of Surgery, UMC Utrecht, Utrecht, <sup>2</sup>Dept. of Surgery, Diaconessenhuis, Utrecht, <sup>3</sup>Dept. of Surgery, Sint Antonius Hospital, Nieuwegein, <sup>4</sup>Dept. of Medical Oncology, UMC Utrecht, Utrecht, <sup>5</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands.
- 11.10 A national cohort study evaluating the association of short-term outcome indicators with long-term survival after esophageal and gastric cancer surgery  
L.R. van der Werf<sup>1</sup>, B.P.L. Wijnhoven<sup>2</sup>, J.W. van Sandick<sup>3</sup>, G.A.P. Nieuwenhuijzen<sup>4</sup>, L.A.D. Busweiler<sup>5</sup>, R. van Hillegersberg<sup>6</sup>, M.W.J.M. Wouters<sup>3</sup>, M.I. van Berge Henegouwen<sup>7</sup>. <sup>1</sup>Dept. of Surgery, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Gastrointestinal Surgery, Erasmus MC, Rotterdam, <sup>3</sup>Dept. of Surgery, Antoni van Leeuwenhoek Hospital, Amsterdam, <sup>4</sup>Dept. of Surgery, Catharina Hospital, Eindhoven, <sup>5</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, <sup>6</sup>Dept. of Surgery, UMC Utrecht, Utrecht, <sup>7</sup>Dept. of Gastrointestinal Surgery, Amsterdam UMC, Amsterdam, The Netherlands.

- 11.20 Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer: a pilot study  
S.E. Vollenbrock<sup>1</sup>, J.M. van Dieren<sup>2</sup>, F.E.M. Voncken<sup>3</sup>, S.T. van Turenhout<sup>2</sup>, L.L. Peppelenbosch-Kodach<sup>4</sup>, K.J. Hartemink<sup>5</sup>, B.M.P. Aleman<sup>3</sup>, R.G.H. Beets-Tan<sup>1</sup>, A. Bartels-Rutten<sup>1</sup>. <sup>1</sup>Dept. of Radiology, <sup>2</sup>Dept. of Gastrointestinal Oncology, <sup>3</sup>Dept. of Radiation Oncology, <sup>4</sup>Dept. of Pathology, <sup>5</sup>Dept. of Surgery, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- 11.30 Direct oral feeding following minimally invasive esophagectomy (NUTRIENT II trial): an international, multicenter, open-label randomized controlled trial.  
L.F.C. Fransen<sup>1</sup>, G.H.K. Berkelmans<sup>1</sup>, A.C.P. Dolmans-Zwartjes<sup>1</sup>, E.A. Kouwenhoven<sup>2</sup>, M.J. van Det<sup>2</sup>, M. Nilsson<sup>3</sup>, G.A.P. Nieuwenhuijzen<sup>1</sup>, M.D.P. Luyer<sup>1</sup>. <sup>1</sup>Dept. of Surgery, Catharina Hospital, Eindhoven, The Netherlands. <sup>2</sup>Dept. of Surgery, Hospitalgroup Twente, Almelo, The Netherlands. <sup>3</sup>Dept. of Surgery, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
- 11.40 The preoperative fecal lipidome but not fecal microbial diversity predicts postoperative ileus in elective colorectal surgery  
D.J. Brinkman<sup>1</sup>, J. Lewis<sup>2</sup>, S.E. Mason<sup>2</sup>, S.J. Cameron<sup>2</sup>, Z. Takats<sup>2</sup>, A. Darzi<sup>2</sup>, W.J. de Jonge<sup>1</sup>, J. Kinross<sup>2</sup>. <sup>1</sup>Dept. of Gastroenterology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Dept. of Surgery, Imperial College, London, United Kingdom.
- 11.50 Adhesion-related hospital readmissions in patients with open or laparoscopic abdominal or pelvic surgery: A nationwide cohort study (SCAR update)  
P. Krielen, M.W.J. Stommel, H. van Goor, R.P.G. ten Broek. Dept. of Surgery, Radboudumc, Nijmegen, The Netherlands.
- 12.00 IMAGINE: Ileus Management International  
S.Z. Kuiper. Dept. of Gastrointestinal Surgery, Maastricht UMC, Maastricht, The Netherlands. On behalf of the EuroSurg Collaborative.
- 12.10 Efficacy and safety of additional autologous Platelet Rich Stroma in transanal mucosal advancement flap repair of complex cryptoglandular anal fistulas  
J.H.C. Arkenbosch<sup>1</sup>, O. van Ruler<sup>2</sup>, W.B. Deijl<sup>2</sup>, H.P. Stevens<sup>3</sup>, A.C. de Vries<sup>1</sup>, C.J. van der Woude<sup>1</sup>, E.J.R. de Graaf<sup>2</sup>, W.R. Schouten<sup>2,4</sup>. <sup>1</sup>Dept. of Gastroenterology, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Colorectal Surgery, IJsselland Hospital, Capelle a/d IJssel, <sup>3</sup>Dept. of Plastic and Reconstructive Surgery, Bergman Clinics, Bilthoven, <sup>4</sup>Dept. of Colorectal Surgery, Erasmus MC, Rotterdam, The Netherlands.
- 12.20 Decline in unnecessary surgery for locally advanced rectal cancer due to adequate multidisciplinary response evaluation following chemo-radiotherapy  
J.F. Huisman<sup>1</sup>, I.J.H. Schoenaker<sup>2</sup>, R.M. Brohet<sup>3</sup>, O. Reerink<sup>4</sup>, H. van der Sluis<sup>1</sup>, F.C.P. Moll<sup>5</sup>, E. de Boer<sup>6</sup>, J.C. de Graaf<sup>7</sup>, G.L. Beets<sup>8</sup>, W.H. de Vos tot Nederveen Cappel<sup>1</sup>, H.L. van Westreenen<sup>9</sup>. <sup>1</sup>Dept. of Gastroenterology and Hepatology, Isala, Zwolle, <sup>2</sup>Dept. of Gastrointestinal Oncology, Isala, Zwolle, <sup>3</sup>Dept. of Epidemiology, Isala, Zwolle, <sup>4</sup>Dept. of Radiotherapy, Isala, Zwolle, <sup>5</sup>Dept. of Pathology, Isala, Zwolle, <sup>6</sup>Dept. of Radiology, Isala, Zwolle, <sup>7</sup>Dept. of Internal Medicine, Isala, Zwolle, <sup>8</sup>Dept. of Surgery, Antoni van Leeuwenhoek, Amsterdam, <sup>9</sup>Dept. of Surgery, Isala, Zwolle, The Netherlands.
- 12.30 Randomised clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (the SELECT trial).  
G.S.A. Abis<sup>1,2</sup>, H.B.A.C. Stockmann<sup>1</sup>, H.J. Bonjer<sup>2</sup>, N. van Veenendaal<sup>2</sup>, M.L.M. van Doorn-Schepens<sup>2</sup>, A.E. Budding<sup>2</sup>, J.A. Wilschut<sup>2</sup>, M. van Egmond<sup>2</sup>, S.J. Oosterling<sup>1</sup>. <sup>1</sup>Dept. of Surgery, Spaarne Gasthuis Haarlem/Hoofddorp. <sup>2</sup> Dept. of Surgery, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
- 12.40 Lunchpauze

Cursuscommissie: Dr. B. Oldenburg, MDL-arts, UMCU, Utrecht, voorzitter  
Dr. E.J.M. van Geenen, Radboudumc, Nijmegen  
Dr. I.L. Holster, aios MDL, Albert Schweitzer, Dordrecht  
Dr. M.A.J.M. Jacobs, MDL-arts, VUmc, Amsterdam  
Dr. Y. Keulemans, MDL-arts, Zuyderland, Heerlen  
Dr. J.F.M. Lange, chirurg, UMCG, Groningen  
Dr. A.M.J. Langers, MDL-arts, LUMC, Leiden  
Drs. M. Radersma, aios MDL, OLVG, Amsterdam  
Dr. B.J. Veldt, MDL-arts, Reinier de Graaf Gasthuis, Delft  
Dr. L.G. van Vlerken, MDL-arts, Antoni van Leeuwenhoek Amsterdam



13.30-13.40 uur      Opening: Dr. B. Oldenburg, MDL-arts, UMCU, Utrecht  
Pre-test vragen

**Onderwerp: Dunne Darm I**

**Voorzitters:**      *Dr. M.A.J.M. Jacobs, MDL-arts, VUmc, Amsterdam*  
                              *Dr. L.G. van Vlerken, MDL-arts, Antoni van Leeuwenhoek, Amsterdam*

13.40-14.00 uur      Coeliakie en gluten-overgevoeligheid  
Prof. dr. G. Bouma, MDL-arts, Amsterdam UMC, VUmc  
*Leerdoelen: nieuwe inzichten die in de richtlijn zouden moeten komen, de waarheid over gluten overgevoeligheid*

14.00-14.20 uur      Beeldvorming van de dunne darm: ballon enteroscopie, video capsule of MRI  
Dr. S.J.B van Weyenberg, MDL-arts, Spaarne Gasthuis, Hoofddorp  
*Leerdoelen: aan de hand van casuïstiek duidelijk maken wanneer welke techniek moet of kan worden ingezet*

14.20-14.40 uur      Bariatrische chirurgie: de chirurg en de endoscopist  
J.A. Apers, chirurg, St. Franciscus, Rotterdam  
*Leerdoelen: overzicht in de verschillende technieken, waarbij de nadruk moet liggen op endoscopische bevindingen, complicaties en beperkingen*

14.40-15.00 uur      Bariatrische chirurgie: complicaties op langere termijn  
Dr. P.J. Wahab, MDL-arts, Rijnstate, Arnhem  
*Leerdoelen: overzicht geven van complicaties op het gebied van deficiënties, bloedingen, obstructies, galstenen en preventieve en therapeutische handreikingen*

15.00-15.30 uur      Pauze

**Onderwerp: Pancreatitis**

- Voorzitters:** Dr. I.L. Holster, aios MDL, Albert Schweitzer, Dordrecht  
Dr. J.F.M. Lange, chirurg, UMCG, Groningen
- 15.30-15.50 uur Pancreatitis, NIET veroorzaakt door galstenen, alcohol of de endoscopist  
Dr. H.R. van Buuren, MDL-arts, Erasmus MC, Rotterdam  
*Leerdoelen: Wanneer dient aan alternatieve diagnoses gedacht te worden, wat is de differentiaal diagnose, welke diagnostiek moet worden ingezet?*
- 15.50-16.10 uur Diagnose en therapie van acute pancreatitis  
Dr. E.J.M. van Geenen, Radboudumc, Nijmegen  
*Leerdoelen: wat is het standaardbeleid aangaande infusiebeleid, voeding, beeldvorming?*
- 16.10-16.30 uur Endoscopische behandeling van complicaties van pancreatitis  
Prof. dr. F.P. Vleggaar, MDL-arts, UMCU, Utrecht  
*Leerdoelen: wat zijn de indicaties voor transgastrische benadering of stenting, hoe dient dit te worden verricht, hoe is de verdere follow up?*
- 16.30-16.50 uur Chronische pancreatitis: pijn en andere complicaties  
Prof. dr. M.A. Boermeester, chirurg, UMCA, locatie AMC, Amsterdam  
*Leerdoelen: indicaties voor interventies (pijn, recidiverende flares ..), keuzes.*
- 16.50-17.20 uur Pauze

**Onderwerp: Dunne Darm II**

- Voorzitters:** Prof. dr. M.A. Boermeester, chirurg, Amsterdam UMC, locatie AMC, Amsterdam  
Drs. M. Radersma, aios MDL, OLVG, Amsterdam
- 17.20-17.40 uur Darmischemie revisited  
Prof. dr. J.J. Kolkman, MDL-arts, Medisch Spectrum Twente, Enschede  
*Leerdoelen: wanneer opnemen in de differentiaal diagnose, hoe te bevestigen, wanneer verwijzen, hoe te behandelen?*
- 17.40-18.00 uur Short Bowel syndroom, TPV en dunne darm transplantatie  
Prof. dr. G. Dijkstra, MDL-arts, UMCG, Groningen  
*Leerdoelen: welke behandelstappen moeten worden gezet bij de behandeling van een short bowel. Wanneer TPV, wanneer Groningen bellen?*
- 18.00-18.20 uur Quiz en prijsuitreiking, sluiting
- 18.30 uur Diner einde cursus: Indisch buffet



Beroepsvereniging van zorgprofessionals

Maag Darm Lever



**Voorzitters :** Mw. T.A. Korpershoek, voorzitter V&VN MDL

**Thema: MDL algemeen**

- 09.30 Algemene ledenvergadering
- 10.10 #MDLISOVERAL  
*Dr. M. ter Borg, MDL-arts, Maxima Medisch Centrum, Eindhoven*
- 10.30 Gastro intestinale stroma tumor (GIST)  
*P.A. Boonstra, aios MDL, Isala ziekenhuis, Zwolle*
- 10.50 Voeding  
*P. Voogt, verpleegkundig specialist, Jeroen Bosch ziekenhuis, 's Hertogenbosch*
- 11.10 Pauze



Beroepsvereniging van zorgprofessionals

Maag Darm Lever



**Voorzitters :** Mw. T.A. Korpershoek, voorzitter V&VN MDL

**Thema: MDL algemeen**

- 11.40 MDL klachten I e lijn  
*Spreker volgt*
- 12.00 Gastroesophageal reflux disease (GERD)  
*Dr. D.P. Hirsch, MDL-arts, Rijnstate, Arnhem*
- 12.20 Leverfunctiestoornissen  
*Dr. B. Baak, MDL-arts, OLVG, Amsterdam*
- 13.00 Pauze





**Voorzitter:** volgt

**Thema: Endoscopie**

- 14.00 Flourecense moluculaire endoscopie  
Spreker volgt
- 14.25 Helicobacter Pylori  
S. Nieuwenburg, promovendus, Erasmus MC, Rotterdam
- 14.50 Endoscopische behandeling van GE-bloedingen  
Dr. F. Wolfhagen, MDL-arts, Albert Schweitzer ziekenhuis, Dordrecht
- 15.15 TI coloncarcinoom, endoscopische opties?  
Dr. A.U.G. van Lent, MDL-arts, OLVG, Amsterdam
- 15.40 Borrel



**Voorzitter:** volgt

**Thema: IBD**

- 14.00 Refractaire proctitis (IFX falers, stamcellen, surveillance)  
Drs. M. Branhoorn, arts-onderzoeker, LUMC, Leiden
- 14.25 Pathologie IBD  
Dr. A. Mookhoek, patholoog i.o., VUmc, Amsterdam
- 14.50 Basisbegrippen genetica, geneticus, oorzaak genetica  
Dr. E.A.M. Festen, MDL-arts, UMCG, Groningen
- 15.15 Tofacitinib  
Spreker volgt
- 15.40 Borrel



Maag Darm Lever



**Voorzitter:** volgt

**Thema: Verpleegkundig endoscopisten**

- 14.00 Irritable Bowel Syndrome  
*Dr. M.H. Otten, MDL-arts, MC de Veluwe, Apeldoorn*
- 14.25 Vaatanomalieën  
*Drs. M.L. Hazen, MDL-arts, Elkerliek, Helmond*
- 14.50 Juridische kader VE  
*Mw. mr. A.J.G.M. Janssen*
- 15.15 Gloucester Comfort Scale  
*Dr. B. den Hartog, MDL-arts, Arnhem*
- 15.40 Borrel